<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Chapter 43: Anticoagulants, Antiplatelets, and Thrombolytics (ADHD Friendly)</title>
    <style>
        @import url('https://fonts.googleapis.com/css2?family=Roboto:wght@300;400;700&family=Open+Sans:wght@400;600&display=swap');

        :root {
            --primary-color: #007bff; /* Blue */
            --secondary-color: #28a745; /* Green */
            --accent-color: #ffc107; /* Yellow */
            --alert-color: #dc3545; /* Red */
            --info-color: #17a2b8; /* Cyan */
            --text-color: #333;
            --bg-light: #f8f9fa;
            --bg-white: #ffffff;
            --border-color: #dee2e6;
            --shadow-light: rgba(0, 0, 0, 0.1);
            --focus-border: #6c757d; /* Gray for focus boxes */
            --quiz-bg: #d4edda; /* Light green for quizzes */
            --reveal-bg: #e9ecef; /* Light gray for revealed content */
            --drug-card-bg: #f0f0f0; /* Light gray for drug quiz card */
            --button-mastered: #28a745; /* Green for Yes */
            --button-missed: #dc3545; /* Red for No */
            --progress-bar-bg: #e0e0e0;
            --progress-bar-fill: #4CAF50; /* Green fill */
            --break-prompt-bg: #ffebee; /* Light red for break prompts */
            --break-prompt-border: #ef9a9a; /* Medium red for border */
        }

        /* Crucial adjustments for iframe scrolling */
        html, body {
            height: 100%; /* Make sure HTML and Body fill the iframe */
            margin: 0;
            padding: 0;
            overflow-x: hidden; /* Prevent horizontal scrollbar */
            overflow-y: auto; /* Allow vertical scrolling within the iframe */
        }

        body {
            font-family: 'Open Sans', sans-serif;
            line-height: 1.6;
            color: var(--text-color);
            background-color: var(--bg-light);
            transition: font-size 0.2s ease, filter 0.5s ease-in-out; /* Smooth text size change and blur */
        }

        /* Styles for blurring the background content */
        body.blurred > *:not(#clockOutOverlay) {
            filter: blur(5px);
            pointer-events: none; /* Disables interaction with blurred content */
            user-select: none; /* Prevents text selection on blurred content */
        }

        .container {
            max-width: 100%; /* Changed to fill screen width */
            margin: 20px auto;
            padding: 20px;
            background-color: var(--bg-white);
            border-radius: 8px;
            box-shadow: 0 4px 15px var(--shadow-light);
            box-sizing: border-box; /* Include padding and border in the element's total width and height */
            min-height: calc(100vh - 40px); /* Ensure container is tall enough to trigger scroll */
        }

        header {
            background-color: var(--primary-color);
            color: white;
            padding: 25px 20px;
            border-radius: 8px 8px 0 0;
            text-align: center;
            margin-bottom: 20px;
            position: relative; /* For progress bar positioning */
        }

        header h1 {
            margin: 0;
            font-family: 'Roboto', sans-serif;
            font-weight: 700;
            font-size: 2.5em;
        }

        /* Module Progress Bar */
        #moduleProgressBarContainer {
            width: 90%;
            height: 10px;
            background-color: var(--progress-bar-bg);
            border-radius: 5px;
            margin: 15px auto 0;
            overflow: hidden;
        }

        #moduleProgressBar {
            height: 100%;
            width: 0%;
            background-color: var(--progress-bar-fill);
            border-radius: 5px;
            transition: width 0.5s ease-in-out;
        }

        nav {
            background-color: var(--secondary-color);
            padding: 10px 0;
            border-radius: 0 0 8px 8px;
            margin-bottom: 20px;
            box-shadow: 0 2px 5px var(--shadow-light);
        }

        nav ul {
            list-style: none;
            padding: 0;
            margin: 0;
            display: flex;
            justify-content: center;
            flex-wrap: wrap;
        }

        nav ul li {
            margin: 5px 15px;
        }

        nav ul li a { /* Updated: No href, so no default link styles needed for href, just cursor */
            color: white;
            text-decoration: none;
            font-weight: 600;
            padding: 8px 12px;
            border-radius: 5px;
            transition: background-color 0.3s ease;
            cursor: default; /* Indicate it's not clickable as a link */
        }

        nav ul li a:hover, nav ul li a.active {
            background-color: rgba(255, 255, 255, 0.2);
            cursor: default; /* Maintain default cursor on hover too */
        }

        nav ul li a.completed {
            background-color: #1e7e34; /* Darker green for completed */
            box-shadow: inset 0 0 5px rgba(0,0,0,0.3);
        }


        h2, h3, h4 {
            font-family: 'Roboto', sans-serif;
            color: var(--primary-color);
            border-bottom: 2px solid var(--border-color);
            padding-bottom: 5px;
            margin-top: 30px;
        }

        h2 {
            font-size: 2em;
        }

        h3 {
            font-size: 1.5em;
        }

        h4 {
            font-size: 1.2em;
            border-bottom: 1px dashed var(--border-color);
            margin-bottom: 15px;
        }

        section {
            margin-bottom: 25px;
            padding: 15px;
            background-color: var(--bg-white);
            border-radius: 8px;
            box-shadow: 0 2px 8px rgba(0, 0, 0, 0.05);
            transition: transform 0.2s ease-in-out;
        }

        section:hover {
            transform: translateY(-3px);
        }

        .objectives ul {
            list-style-type: disc;
            padding-left: 20px;
        }

        .objective-item {
            margin-bottom: 8px;
        }

        .info-card {
            background-color: var(--bg-light);
            border-left: 5px solid var(--info-color);
            padding: 15px;
            margin: 20px 0;
            border-radius: 5px;
        }

        .reveal-button {
            background-color: var(--accent-color);
            color: var(--text-color);
            border: none;
            padding: 10px 15px;
            border-radius: 5px;
            cursor: pointer;
            font-size: 1em;
            margin-top: 10px;
            transition: background-color 0.3s ease;
            display: block; /* Make button full width */
            width: fit-content; /* Adjust width to content */
        }

        .reveal-button:hover {
            background-color: #ffda6a;
        }

        .reveal-content {
            display: none;
            margin-top: 15px;
            padding: 15px;
            background-color: var(--reveal-bg);
            border-left: 3px solid var(--secondary-color);
            border-radius: 5px;
        }

        .question-card {
            background-color: var(--quiz-bg);
            border: 1px solid #c3e6cb;
            padding: 20px;
            margin: 30px 0;
            border-radius: 8px;
            box-shadow: 0 2px 10px rgba(0, 0, 0, 0.1);
        }

        .question-card p {
            font-weight: 600;
            color: #155724;
            margin-bottom: 15px;
        }

        .question-card .options label {
            display: block;
            margin-bottom: 10px;
            cursor: pointer;
        }

        .question-card .options input[type="radio"],
        .question-card .options input[type="checkbox"] {
            margin-right: 8px;
        }

        .question-card .feedback {
            margin-top: 15px;
            padding: 10px;
            border-radius: 5px;
            display: none;
        }

        .question-card .feedback.correct {
            background-color: #d1ecf1; /* light blue */
            color: #0c5460; /* dark blue */
            border: 1px solid #bee5eb;
        }

        .question-card .feedback.incorrect {
            background-color: #f8d7da; /* light red */
            color: #721c24; /* dark red */
            border: 1px solid #f5c6cb;
        }

        .question-card .submit-btn {
            background-color: var(--primary-color);
            color: white;
            border: none;
            padding: 10px 20px;
            border-radius: 5px;
            cursor: pointer;
            margin-top: 15px;
            transition: background-color 0.3s ease;
        }

        .question-card .submit-btn:hover {
            background-color: #0056b3;
        }


        .prototype-drug-chart-container {
            border: 1px solid var(--border-color);
            border-collapse: collapse;
            width: 100%;
            margin: 20px 0;
            font-size: 0.9em;
        }

        .prototype-drug-chart-container th, .prototype-drug-chart-container td {
            border: 1px solid var(--border-color);
            padding: 8px;
            text-align: left;
        }

        .prototype-drug-chart-container th {
            background-color: var(--primary-color);
            color: white;
            font-weight: bold;
        }

        .prototype-drug-chart-container tr:nth-child(even) {
            background-color: #f2f2f2;
        }

        .note, .focus-prompt, .quick-fact {
            padding: 15px;
            margin: 20px 0;
            border-radius: 5px;
            font-weight: 600;
        }

        .note {
            background-color: #fff3cd;
            border-left: 5px solid #ffc107;
            color: #856404;
        }

        .focus-prompt {
            background-color: #d1ecf1; /* light blue */
            border-left: 5px solid #0c5460; /* dark blue */
            color: #0c5460;
        }

        .quick-fact {
            background-color: #e2f0d9; /* very light green */
            border-left: 5px solid #6ab04c; /* medium green */
            color: #4a7d32;
        }

        .highlight {
            background-color: #ffe082; /* Light yellow for highlighting key terms */
            padding: 2px 4px;
            border-radius: 3px;
        }

        .nclex-next-gen {
            background-color: #e6f7ff;
            border: 2px solid #a6d9f5;
            padding: 25px;
            margin: 40px 0;
            border-radius: 10px;
            box-shadow: 0 4px 12px rgba(0, 0, 0, 0.08);
        }

        .nclex-next-gen h3 {
            color: #2196f3;
            border-bottom: 1px dashed #a6d9f5;
            padding-bottom: 10px;
            margin-top: 0;
            margin-bottom: 20px;
        }

        .nclex-next-gen .case-study {
            margin-bottom: 20px;
            font-style: italic;
        }

        .nclex-next-gen .fill-in-the-blank {
            margin-top: 20px;
        }

        .nclex-next-gen .fill-in-the-blank textarea {
            width: calc(100% - 20px);
            min-height: 80px;
            padding: 8px;
            border: 1px solid var(--border-color);
            border-radius: 4px;
            margin-top: 10px;
            font-family: 'Open Sans', sans-serif;
            font-size: 0.95em;
            resize: vertical;
        }

        .nclex-next-gen .fill-in-the-blank button {
            margin-top: 15px;
        }

        .nclex-next-gen .rationale {
            background-color: #e0f2f7;
            border-left: 4px solid #4a90e2;
            padding: 15px;
            margin-top: 20px;
            border-radius: 5px;
            display: none;
        }

        .nclex-next-gen .rationale p {
            margin: 0;
            font-size: 0.95em;
        }

        .figure-placeholder {
            text-align: center;
            margin: 20px 0;
            padding: 15px;
            background-color: #eef;
            border: 1px dashed #bbb;
            border-radius: 5px;
            color: #666;
            font-style: italic;
        }

        .recap {
            background-color: #f0f8ff; /* Lighter blue */
            border-left: 5px solid #add8e6; /* Light steel blue */
            padding: 15px;
            margin: 25px 0;
            border-radius: 5px;
            font-weight: 500;
        }
        .recap h4 {
            color: #36a2eb;
            border-bottom: 1px solid #add8e6;
        }


        footer {
            text-align: center;
            padding: 20px;
            margin-top: 30px;
            background-color: var(--primary-color);
            color: white;
            border-radius: 0 0 8px 8px;
        }

        /* Tooltip styles */
        .tooltip-container {
            position: relative;
            display: inline-block;
            cursor: help;
            border-bottom: 1px dotted var(--primary-color); /* Underline for tooltips */
        }

        .tooltip-text {
            visibility: hidden;
            width: 250px;
            background-color: #555;
            color: #fff;
            text-align: center;
            border-radius: 6px;
            padding: 5px 10px;
            position: absolute;
            z-index: 1;
            bottom: 125%; /* Position above the text */
            left: 50%;
            margin-left: -125px; /* Center the tooltip */
            opacity: 0;
            transition: opacity 0.3s;
            font-size: 0.85em;
        }

        .tooltip-text::after {
            content: "";
            position: absolute;
            top: 100%; /* At the bottom of the tooltip */
            left: 50%;
            margin-left: -5px;
            border-width: 5px;
            border-style: solid;
            border-color: #555 transparent transparent transparent;
        }

        .tooltip-container:hover .tooltip-text {
            visibility: visible;
            opacity: 1;
        }

        /* Drug Mastery Quiz Specific Styles */
        #drug-mastery-quiz .quiz-card {
            background-color: var(--drug-card-bg);
            border: 1px solid var(--primary-color);
            padding: 25px;
            margin: 30px auto;
            border-radius: 10px;
            box-shadow: 0 5px 15px rgba(0, 0, 0, 0.15);
            max-width: 600px;
            display: none; /* Hidden until quiz starts */
            text-align: center;
        }

        #drug-mastery-quiz .quiz-card h4 {
            color: var(--primary-color);
            margin-bottom: 10px;
            font-size: 1.8em;
            border-bottom: none; /* Override default h4 border */
        }

        #drug-mastery-quiz .quiz-card p {
            font-size: 1.2em;
            margin-bottom: 20px;
            font-weight: normal;
        }

        #drug-mastery-quiz .quiz-controls {
            margin-top: 20px;
            display: flex;
            justify-content: space-around;
            gap: 10px;
        }

        #drug-mastery-quiz .quiz-controls button {
            flex: 1;
            padding: 12px 20px;
            border: none;
            border-radius: 8px;
            font-size: 1.1em;
            cursor: pointer;
            transition: background-color 0.3s ease, transform 0.1s ease;
        }

        #drug-mastery-quiz .quiz-controls button:active {
            transform: translateY(1px);
        }

        #drug-mastery-quiz #startQuizBtn {
            background-color: var(--secondary-color);
            color: white;
            display: block;
            margin: 20px auto;
            width: fit-content;
            padding: 15px 30px;
            font-size: 1.4em;
        }
        #drug-mastery-quiz #startQuizBtn:hover {
            background-color: #218838;
        }

        #drug-mastery-quiz #showAnswerBtn {
            background-color: var(--accent-color);
            color: var(--text-color);
        }
        #drug-mastery-quiz #showAnswerBtn:hover {
            background-color: #e0a800;
        }

        #drug-mastery-quiz #answerFeedback {
            margin-top: 20px;
            padding: 15px;
            border-radius: 8px;
            background-color: var(--reveal-bg);
            border: 1px dashed var(--info-color);
            text-align: left;
            display: none;
        }

        #drug-mastery-quiz #answerFeedback h5 {
            margin-top: 0;
            color: var(--primary-color);
            font-size: 1.1em;
        }

        #drug-mastery-quiz #masteryButtons {
            margin-top: 20px;
            display: flex;
            justify-content: space-around;
            gap: 10px;
        }

        #drug-mastery-quiz #masteryButtons button {
            flex: 1;
            padding: 12px 20px;
            border: none;
            border-radius: 8px;
            font-size: 1.1em;
            cursor: pointer;
        }
        #drug-mastery-quiz #masteryButtons button#correctBtn {
            background-color: var(--button-mastered);
            color: white;
        }
        #drug-mastery-quiz #masteryButtons button#correctBtn:hover {
            background-color: #218838;
        }
        #drug-mastery-quiz #masteryButtons button#incorrectBtn {
            background-color: var(--button-missed);
            color: white;
        }
        #drug-mastery-quiz #masteryButtons button#incorrectBtn:hover {
            background-color: #c82333;
        }

        /* Removed #nextCardBtn from quiz styles as it's now automatic */

        #drug-mastery-quiz #quizSummary {
            display: none;
            padding: 25px;
            background-color: #e6ffe6; /* Light green for success */
            border: 2px solid var(--secondary-color);
            border-radius: 10px;
            text-align: center;
        }
        #drug-mastery-quiz #quizSummary h4 {
            color: var(--secondary-color);
            font-size: 2em;
            margin-bottom: 15px;
            border-bottom: none;
        }
        #drug-mastery-quiz #quizSummary p {
            font-size: 1.2em;
            margin-bottom: 10px;
        }
        #drug-mastery-quiz #quizSummary button {
            margin: 10px;
            padding: 12px 25px;
            border-radius: 8px;
            font-size: 1.1em;
            cursor: pointer;
            border: none;
        }
        #drug-mastery-quiz #quizSummary button#restartQuizBtn {
            background-color: var(--primary-color);
            color: white;
        }
        #drug-mastery-quiz #quizSummary button#restartQuizBtn:hover {
            background-color: #0056b3;
        }
        #drug-mastery-quiz #quizSummary button#reviewMissedBtn {
            background-color: var(--alert-color);
            color: white;
        }
        #drug-mastery-quiz #quizSummary button#reviewMissedBtn:hover {
            background-color: #c82333;
        }

        #drug-mastery-quiz .progress-tracker {
            font-size: 0.9em;
            color: #666;
            margin-bottom: 15px;
        }

        /* ADHD-specific additions */
        .quick-note-area {
            background-color: #f7f7f7;
            border: 1px dashed #ccc;
            padding: 15px;
            margin: 20px 0;
            border-radius: 8px;
        }

        .quick-note-area h3 {
            color: #666;
            border-bottom: 1px solid #ddd;
            margin-top: 0;
        }

        .quick-note-area textarea {
            width: calc(100% - 10px);
            min-height: 100px;
            padding: 5px;
            border: 1px solid #ddd;
            border-radius: 4px;
            font-family: 'Open Sans', sans-serif;
            font-size: 0.95em;
            resize: vertical; /* Allow vertical resizing */
        }

        .text-size-controls {
            text-align: right;
            margin-bottom: 10px;
        }

        .text-size-controls button {
            background-color: #6c757d;
            color: white;
            border: none;
            padding: 5px 10px;
            border-radius: 44px;
            cursor: pointer;
            font-size: 0.9em;
            margin-left: 5px;
        }

        .micro-break-prompt {
            position: fixed;
            bottom: 20px;
            left: 50%;
            transform: translateX(-50%);
            background-color: var(--break-prompt-bg);
            border: 2px solid var(--break-prompt-border);
            padding: 15px 25px;
            border-radius: 10px;
            box-shadow: 0 4px 10px rgba(0, 0, 0, 0.1);
            z-index: 1000;
            font-weight: bold;
            color: var(--alert-color);
            display: none; /* Hidden by default */
            animation: fadeInOut 8s forwards; /* Animation */
        }

        @keyframes fadeInOut {
            0% { opacity: 0; transform: translateX(-50%) translateY(20px); }
            10% { opacity: 1; transform: translateX(-50%) translateY(0); }
            90% { opacity: 1; transform: translateX(-50%) translateY(0); }
            100% { opacity: 0; transform: translateX(-50%) translateY(20px); }
        }

        /* Clock Out Overlay Styles (Revised for improved centering and appearance) */
        #clockOutOverlay {
            position: fixed;
            top: 0;
            left: 0;
            width: 100%;
            height: 100%;
            background-color: rgba(0, 0, 0, 0.7); /* Dark semi-transparent overlay */
            display: flex;
            justify-content: center;
            align-items: center;
            z-index: 10000; /* Make sure it's on top of everything */
            /* Start hidden and transition in */
            visibility: hidden;
            opacity: 0;
            transition: visibility 0s 0.5s, opacity 0.5s ease-out; /* Delay visibility transition for smooth fade out */
        }

        #clockOutOverlay.active {
            visibility: visible;
            opacity: 1;
            transition: visibility 0s, opacity 0.5s ease-in; /* No delay for fade in */
        }

        #clockOutContent {
            background-color: var(--bg-white);
            color: var(--text-color);
            padding: 40px;
            border-radius: 10px;
            box-shadow: 0 5px 25px rgba(0, 0, 0, 0.4);
            text-align: center;
            max-width: 400px;
            width: 90%; /* Responsive width */
            /* Add some initial transform to make it "pop" when appearing */
            transform: scale(0.9) translateY(20px);
            opacity: 0;
            transition: transform 0.5s ease-out, opacity 0.5s ease-out;
        }

        #clockOutOverlay.active #clockOutContent {
            transform: scale(1) translateY(0);
            opacity: 1;
        }

        #clockOutContent h2 {
            color: var(--primary-color);
            font-family: 'Roboto', sans-serif; /* Ensure Roboto font */
            font-size: 2.8em; /* Slightly larger for impact */
            margin-top: 0;
            border-bottom: none; /* Override default h2 border */
        }

        #brainEmoji {
            font-size: 6em; /* Make the emoji very large */
            margin: 20px 0;
            display: block; /* Ensure it takes full width for margin auto */
            animation: floatUpDown 2s infinite alternate ease-in-out; /* Gentle animation */
        }

        @keyframes floatUpDown {
            0% { transform: translateY(0); }
            100% { transform: translateY(-15px); } /* Increased float */
        }

        #countdownTimer {
            font-family: 'Roboto', monospace; /* Monospace for consistent digit width */
            font-size: 4.5em; /* Slightly larger timer */
            font-weight: 700;
            color: var(--alert-color); /* Red for urgency */
            margin: 20px 0;
        }

        /* Mobile Responsiveness for Clock Out */
        @media (max-width: 500px) {
            #clockOutContent {
                padding: 25px; /* Smaller padding on small screens */
            }
            #clockOutContent h2 {
                font-size: 2em;
            }
            #brainEmoji {
                font-size: 4em;
            }
            #countdownTimer {
                font-size: 3.5em;
            }
        }


        /* Mobile Responsiveness for overall layout */
        @media (max-width: 768px) {
            .container {
                margin: 10px;
                padding: 10px;
            }

            header h1 {
                font-size: 1.8em;
            }

            nav ul {
                flex-direction: column;
            }

            nav ul li {
                margin: 5px 0;
            }

            .prototype-drug-chart-container {
                display: block;
                width: 100%;
                overflow-x: auto;
                -webkit-overflow-scrolling: touch;
            }

            .prototype-drug-chart-container thead {
                display: none;
            }

            .prototype-drug-chart-container tbody tr {
                display: block;
                margin-bottom: 10px;
                border: 1px solid var(--border-color);
                border-radius: 5px;
            }

            .prototype-drug-chart-container tbody td {
                display: block;
                text-align: right;
                padding-left: 50%;
                position: relative;
            }

            .prototype-drug-chart-container tbody td::before {
                content: attr(data-label);
                position: absolute;
                left: 10px;
                width: calc(50% - 20px);
                padding-right: 10px;
                white-space: nowrap;
                text-align: left;
                font-weight: bold;
            }

            .micro-break-prompt {
                width: 90%;
                left: 5%;
                transform: translateX(0%);
            }
        }
    </style>
</head>
<body>
    <div class="container">
        <header>
            <h1>Chapter 43: Anticoagulants, Antiplatelets, and Thrombolytics</h1>
            <p>Mastering Medications for Clotting Disorders - ADHD Friendly!</p>
            <div id="moduleProgressBarContainer">
                <div id="moduleProgressBar"></div>
            </div>
        </header>

        <nav>
            <ul>
                <li><a id="nav-objectives">Objectives</a></li>
                <li><a id="nav-introduction">Intro</a></li>
                <li><a id="nav-thrombus-formation">Patho: Thrombus</a></li>
                <li><a id="nav-anticoagulants">Anticoagulants</a></li>
                <li><a id="nav-heparin">Heparin</a></li>
                <li><a id="nav-lmwh">LMWH</a></li>
                <li><a id="nav-dtis">Direct Thrombin Inh.</a></li>
                <li><a id="nav-oral-anticoagulants">Oral Anticoag.</a></li>
                <li><a id="nav-factor-xa-inhibitors">Factor Xa Inh.</a></li>
                <li><a id="nav-nursing-process-anticoag">NP: Anticoagulants</a></li>
                <li><a id="nav-anticoagulant-antagonists">Anticoag. Antagonists</a></li>
                <li><a id="nav-antiplatelet-drugs">Antiplatelets</a></li>
                <li><a id="nav-thrombolytics">Thrombolytics</a></li>
                <li><a id="nav-nursing-process-thrombolytics">NP: Thrombolytics</a></li>
                <li><a id="nav-case-study">Case Study</a></li>
                <li><a id="nav-review-questions">Review Qs</a></li>
                <li><a id="nav-drug-mastery-quiz">Drug Challenge!</a></li>
            </ul>
        </nav>

        <div class="text-size-controls">
            <button id="increaseText">A+</button>
            <button id="decreaseText">A-</button>
        </div>

        <div class="micro-break-prompt" id="microBreakPrompt">
            Quick Break! Stand up and stretch, or take a few deep breaths!
        </div>

        <section id="objectives" class="objectives">
            <h2>Your Learning Adventure Starts Here!</h2>
            <p>By the end of this module, you'll be able to:</p>
            <ul>
                <li class="objective-item"><strong>Compare the actions of anticoagulants, antiplatelets, and thrombolytics.</strong></li>
                <li class="objective-item"><strong>Differentiate the side effects and adverse reactions</strong> of anticoagulants, antiplatelets, and thrombolytics.</li>
                <li class="objective-item"><strong>Apply the Clinical Judgment [Nursing Process]</strong>, including patient teaching, for anticoagulants and thrombolytics.</li>
            </ul>
            <p class="note"><strong>Bonus!</strong> For extra info and cool tools, check out <a href="http://evolve.elsevier.com/McCuistion/pharmacology" target="_blank">evolve.elsevier.com/McCuistion/pharmacology</a></p>
        </section>

        <div class="quick-note-area">
            <h3>Quick Notes / Brain Dump Space</h3>
            <textarea id="quickNotesTextarea" placeholder="Jot down thoughts, questions, or key takeaways here... (Note: These will try to save to your browser's local storage, but backup important info!)"></textarea>
        </div>

        <section id="introduction">
            <h2>1. Introduction: Managing the Flow</h2>
            <div class="info-card">
                <p>Maintaining or restoring healthy blood circulation is crucial, and various drugs help us do just that! These medications fall into three major groups, each with a unique role in managing blood clots:</p>
                <ol>
                    <li><span class="highlight"><strong>Anticoagulants:</strong></span> These drugs work to prevent the formation of new blood clots that could block circulation. Think of them as traffic controllers, keeping new jams from forming.</li>
                    <li><span class="highlight"><strong>Antiplatelets (Antithrombotics):</strong></span> These drugs specifically prevent platelets from sticking together (aggregating) and clumping to form a clot. They stop the initial pile-up of "sticky cells."</li>
                    <li><span class="highlight"><strong>Thrombolytics:</strong></span> Appropriately called "clot busters," these powerful medications attack and dissolve blood clots that have already formed. They're like the tow trucks clearing an existing traffic jam.</li>
                </ol>
                <p>Each of these important drug groups will be discussed separately in this module.</p>
            </div>
            <div class="recap">
                <h4>Recap: Introduction</h4>
                <ul>
                    <li>Three main drug groups for circulation: Anticoagulants (prevent new clots), Antiplatelets (prevent platelet clumping), Thrombolytics (dissolve existing clots).</li>
                </ul>
            </div>
        </section>

        <section id="thrombus-formation">
            <h2>2. Pathophysiology: Thrombus Formation – How Clots Happen</h2>
            <div class="info-card">
                <p><span class="tooltip-container">Thrombosis<span class="tooltip-text">The formation of a blood clot (thrombus) inside a blood vessel, obstructing blood flow.</span></span> is simply the formation of a clot within an artery or vein. These clots can disrupt blood flow and cause serious problems.</p>
                <button class="reveal-button">Arterial vs. Venous Clots: What's the Difference?</button>
                <div class="reveal-content">
                    <h4>Arterial Thrombus Formation:</h4>
                    <p>Arterial clots often form due to:</p>
                    <ul>
                        <li><span class="highlight"><strong>Blood stasis:</strong></span> Decreased circulation, allowing blood to pool.</li>
                        <li><span class="highlight"><strong>Platelet aggregation:</strong></span> Platelets sticking together on the blood vessel wall. This is usually the initiating step.</li>
                        <li><span class="highlight"><strong>Blood coagulation:</strong></span> The subsequent process of fibrin formation.</li>
                    </ul>
                    <p>Arterial clots typically consist of both white clots (platelets) initiating the process, followed by fibrin formation trapping red blood cells in a mesh.</p>
                    <p>The thrombus inhibits blood flow. As it grows, fibrin, platelets, and red blood cells surround it, making it larger and more occlusive. This leads to <span class="tooltip-container">tissue ischemia<span class="tooltip-text">Insufficient blood supply to an organ or tissue, usually due to blocked arteries, leading to a lack of oxygen and nutrients.</span></span> (lack of oxygen to tissues).</p>
                    <h4>Venous Thrombus Formation:</h4>
                    <p>Venous clots usually develop because of <span class="highlight"><strong>slow blood flow (stasis)</strong></span> and can form very rapidly. They primarily consist of platelet aggregation with fibrin that attaches to red blood cells.</p>
                    <div class="focus-prompt">
                        <h4>Key Danger: Embolus!</h4>
                        <p>Both arterial and venous thrombi can be dislodged from the vessel wall and become an <span class="tooltip-container">embolus<span class="tooltip-text">A blood clot, air bubble, piece of fatty deposit, or other object that has been carried in the bloodstream to lodge in a vessel and cause an embolism.</span></span> – a moving blood clot traveling through the bloodstream.</p>
                        <p>Small pieces of a venous clot can detach and travel to the pulmonary artery, leading to the lung. This can result in **inadequate oxygenation and gas exchange in the lungs** (a pulmonary embolism).</p>
                    </div>
                    <h4>The Role of Platelets in Clotting:</h4>
                    <p>Platelets don't normally stick together. This only happens when there's a break in the endothelial lining of a blood vessel. When they adhere to a damaged surface:</p>
                    <ul>
                        <li>They synthesize <span class="highlight"><strong>thromboxane A2 (TxA2)</strong></span>, a potent product of prostaglandins that stimulates more platelet aggregation.</li>
                        <li>They also activate the <span class="highlight"><strong>glycoprotein IIb/IIIa (GP IIb/IIIa) receptor</strong></span>, which binds fibrinogen and promotes platelet clumping.</li>
                        <li><span class="highlight">Adenosine diphosphate (ADP)</span> also increases the activation of this receptor.</li>
                    </ul>
                    <div class="note">
                        <h4>Drug Focus Tip:</h4>
                        <p><strong>Oral and parenteral anticoagulants</strong> (like warfarin and heparin) primarily prevent **venous thrombosis**.</p>
                        <p><strong>Antiplatelet drugs</strong> primarily prevent **arterial thrombosis**.</p>
                        <p>However, both types of drugs suppress thrombosis in general.</p>
                    </div>
                </div>
            </div>
            <div class="recap">
                <h4>Recap: Thrombus Formation</h4>
                <ul>
                    <li>Thrombosis: clot formation in artery/vein.</li>
                    <li>Arterial clots: blood stasis, platelet aggregation (white clots), fibrin (red clots) → tissue ischemia.</li>
                    <li>Venous clots: slow blood flow, platelet aggregation + fibrin → can embolize to lungs (PE).</li>
                    <li>Platelets initiate clotting via thromboxane A2 and GP IIb/IIIa receptors (activated by TxA2, ADP).</li>
                    <li>Anticoagulants focus on venous, Antiplatelets on arterial, but both suppress thrombosis.</li>
                </ul>
            </div>
        </section>

        <section id="anticoagulants">
            <h2>3. Anticoagulants: Preventing the Clotting Cascade</h2>
            <div class="info-card">
                <p><span class="tooltip-container">Anticoagulants<span class="tooltip-text">Medications that prevent the formation of new blood clots or the extension of existing clots. They do NOT dissolve existing clots.</span></span> are drugs used to inhibit clot formation. Unlike thrombolytics (clot busters), they do not dissolve clots that have already formed. Their main role is **prophylactic** – to prevent new clots from forming or existing clots from growing larger.</p>
                <button class="reveal-button">Who Needs Anticoagulants and How Are They Given?</button>
                <div class="reveal-content">
                    <h4>Indications for Anticoagulant Use:</h4>
                    <p>Anticoagulants are used in patients at high risk for clot formation due to various venous and arterial disorders:</p>
                    <ul>
                        <li><strong>Venous problems:</strong>
                            <ul>
                                <li>Deep Venous Thrombosis (DVT)</li>
                                <li>Pulmonary Embolism (PE)</li>
                                <li>Thrombophlebitis</li>
                            </ul>
                        </li>
                        <li><strong>Arterial problems:</strong>
                            <ul>
                                <li>Coronary thrombosis (Myocardial Infarction - MI)</li>
                                <li>Presence of artificial heart valves</li>
                                <li>Cerebrovascular Accident (CVA) or stroke (prevention of ischemic stroke)</li>
                            </ul>
                        </li>
                    </ul>
                    <h4>Administration:</h4>
                    <p>Anticoagulants can be administered either:</p>
                    <ul>
                        <li><strong>Orally (PO):</strong> For long-term management (e.g., warfarin, newer oral anticoagulants).</li>
                        <li><strong>Parenterally:</strong> Subcutaneously (e.g., LMWH) or intravenously (IV) (e.g., heparin, some direct thrombin inhibitors).</li>
                    </ul>
                </div>
            </div>
            <div class="recap">
                <h4>Recap: Anticoagulants</h4>
                <ul>
                    <li>Prevent new clot formation, don't dissolve existing ones.</li>
                    <li>Used prophylactically for high-risk venous (DVT, PE) and arterial (MI, artificial heart valves, stroke) conditions.</li>
                    <li>Administered orally or parenterally (subcut, IV).</li>
                </ul>
            </div>
        </section>

        <section id="heparin">
            <h2>4. Heparin: The Rapid Anticoagulant</h2>
            <div class="info-card">
                <p><span class="tooltip-container">Heparin<span class="tooltip-text">A naturally occurring anticoagulant that prevents clot formation by enhancing the activity of antithrombin III, thereby inhibiting thrombin and other clotting factors. Given parenterally.</span></span>, discovered in 1938, is a natural substance produced in the liver that prevents clot formation. It was initially used to prevent clotting during blood transfusions.</p>
                <button class="reveal-button">Heparin: Actions, Uses, & Monitoring</button>
                <div class="reveal-content">
                    <h4>Indications for Heparin:</h4>
                    <ul>
                        <li>For a **rapid anticoagulant effect** when a thrombosis occurs (e.g., DVT, PE, or an evolving stroke).</li>
                        <li>Used in open-heart surgery to prevent blood clotting.</li>
                        <li>In critically ill patients with <span class="tooltip-container">disseminated intravascular coagulation (DIC)<span class="tooltip-text">A serious disorder in which the proteins that control blood clotting become overactive. It causes small blood clots to form throughout the body, leading to depletion of clotting factors and subsequent severe bleeding.</span></span> (where clots form throughout the body, depleting clotting factors and causing excess bleeding).</li>
                        <li>**Primary use:** Preventing venous thrombosis (which can lead to PE or stroke).</li>
                    </ul>
                    <h4>Mechanism of Action:</h4>
                    <p>Heparin works by combining with <span class="highlight"><strong>antithrombin III</strong></span>, a natural anticoagulant. This combination significantly accelerates the anticoagulant cascade of reactions, primarily preventing thrombin's action. By inhibiting thrombin, the conversion of fibrinogen to fibrin does not occur, thus preventing the formation of a fibrin clot.</p>
                    <div class="figure-placeholder">
                        <h4>Visualize It!</h4>
                        <p><strong>FIG. 43.1:</strong> Action of the parenteral anticoagulant heparin. (Imagine a diagram showing Heparin + Antithrombin III inhibiting Thrombin and preventing Fibrinogen to Fibrin conversion.)</p>
                    </div>
                    <h4>Pharmacokinetics & Administration:</h4>
                    <ul>
                        <li>Poorly absorbed through the GI mucosa and destroyed by the liver enzyme heparinase.</li>
                        <li><strong>Not given orally.</strong> Administered:
                            <ul>
                                <li>**Subcutaneously:** For prophylaxis (e.g., DVT prevention).</li>
                                <li><strong>Intravenously (IV):</strong> To treat acute thrombosis (as a bolus or continuous infusion).</li>
                            </ul>
                        </li>
                        <li>Its half-life is dose-related (30-150 minutes, but can be prolonged with high doses).</li>
                    </ul>
                    <h4>Monitoring Heparin Therapy:</h4>
                    <ul>
                        <li>Heparin prolongs clotting time.</li>
                        <li>Laboratory tests used to monitor heparin therapy and detect deficiencies of clotting factors:
                            <ul>
                                <li><span class="highlight"><strong>Partial Thromboplastin Time (PTT)</strong></span></li>
                                <li><span class="highlight"><strong>Activated Partial Thromboplastin Time (aPTT)</strong></span></li>
                            </ul>
                            **Therapeutic range for aPTT:** 1.5 to 2.5 times the control value (or 30-85 seconds, depending on institutional labs).</li>
                        <li>Heparin can decrease platelet count, leading to <span class="tooltip-container">thrombocytopenia<span class="tooltip-text">A condition in which you have a low blood platelet count. Platelets are colorless blood cells that help blood clot.</span></span>.</li>
                    </ul>
                    <h4>Side Effects and Adverse Reactions:</h4>
                    <ul>
                        <li><strong>Common:</strong> Itching, chills, headache, epistaxis (nosebleed), erythema (redness), hematoma, hematemesis (vomiting blood), hematuria (blood in urine), alopecia (hair loss), elevated hepatic enzymes, nausea, vomiting, injection-site reaction, priapism (prolonged erection).</li>
                        <li><strong>Serious:</strong> Bleeding, intracranial bleeding, ocular hemorrhage, anemia, bone fractures, osteoporosis (with long-term use), hyperkalemia, vitamin D deficiency, GI bleeding, hyperlipidemia, stroke.</li>
                        <li><strong>Life-threatening:</strong> Anaphylaxis, <span class="tooltip-container">Heparin-Induced Thrombocytopenia (HIT)<span class="tooltip-text">A serious, immune-mediated adverse drug reaction caused by heparin, leading to a significant drop in platelet count and an increased risk of thrombosis.</span></span>, severe hemorrhage.</li>
                    </ul>
                    <h4>Antidote for Heparin Overdose:</h4>
                    <p>If severe hemorrhage occurs during heparin therapy, the anticoagulant antagonist <span class="highlight"><strong>protamine sulfate</strong></span> is given by IV. Protamine sulfate works by reversing the action of heparin. The dosage is typically 1 mg of protamine sulfate for every 100 units of unfractionated heparin to be neutralized.</p>
                    <h4>Transitioning off Heparin:</h4>
                    <p>Before discontinuing heparin, oral therapy with warfarin is typically started to provide overlapping anticoagulation as warfarin takes time to reach therapeutic levels.</p>
                </div>
            </div>
            <div class="recap">
                <h4>Recap: Heparin</h4>
                <ul>
                    <li>Natural substance, prevents clot formation by combining with antithrombin III, inhibiting thrombin.</li>
                    <li>**Uses:** Rapid anticoagulation (DVT, PE, stroke), open-heart surgery, DIC. Primary: prevent venous thrombosis.</li>
                    <li>**Admin:** Subcut (prophylaxis), IV (acute). NOT oral.</li>
                    <li>**Monitor:** PTT/aPTT (therapeutic 1.5-2.5x control), platelet count (for HIT).</li>
                    <li>**Side Effects:** Bleeding, hematoma, elevated liver enzymes. **Life-threatening:** Anaphylaxis, HIT, hemorrhage.</li>
                    <li>**Antidote:** Protamine sulfate.</li>
                    <li>Overlap with warfarin when discontinuing.</li>
                </ul>
            </div>
        </section>

        <section id="lmwh">
            <h2>5. Low-Molecular-Weight Heparins (LMWHs)</h2>
            <div class="info-card">
                <p>LMWHs are derivatives of standard heparin designed to offer more stable responses and a lower risk of bleeding, making them safer and easier for home administration.</p>
                <button class="reveal-button">LMWHs: Better Heparin?</button>
                <div class="reveal-content">
                    <h4>Key Characteristics:</h4>
                    <ul>
                        <li>Produced by extracting low-molecular-weight fractions of standard heparin through depolymerization.</li>
                        <li>Produce more stable responses at recommended doses compared to unfractionated heparin.</li>
                        <li><span class="highlight"><strong>Less frequent laboratory monitoring (aPTT is NOT required)</strong></span> because LMWH does not have the same effect on aPTT as standard heparin.</li>
                        <li>Half-life is two to four times longer than that of unfractionated heparin.</li>
                        <li>Bleeding risk is lower than with unfractionated heparin.</li>
                    </ul>
                    <h4>Mechanism of Action:</h4>
                    <p>Similar to heparin, LMWH prevents coagulation by combining with antithrombin III, but it primarily inactivates <span class="highlight"><strong>Factor Xa</strong></span>. It is less able to inactivate thrombin directly, which contributes to its more predictable anticoagulant effect.</p>
                    <h4>Examples of LMWHs:</h4>
                    <ul>
                        <li><span class="highlight"><strong>Enoxaparin (Lovenox)</strong></span></li>
                        <li><span class="highlight"><strong>Dalteparin</strong></span></li>
                    </ul>
                    <div class="patient-safety note">
                        <h4>Patient Safety: Do Not Confuse...</h4>
                        <ul>
                            <li><strong>Enoxaparin</strong> (LMWH) with <strong>Enoxacin</strong> (a fluoroquinolone antibiotic).</li>
                            <li><strong>Lovenox</strong> (an LMWH) with <strong>Lotronex</strong> (a gastrointestinal drug).</li>
                        </ul>
                    </div>
                    <h4>Fondaparinux: A Related Selective Factor Xa Inhibitor</h4>
                    <ul>
                        <li>Synthetically engineered antithrombotic.</li>
                        <li>Categorized as a <span class="highlight"><strong>selective factor Xa inhibitor</strong></span>.</li>
                        <li>Related in structure to heparin and LMWHs.</li>
                        <li>Effective as a **once-daily subcutaneous injection**.</li>
                        <li>Used for similar purposes as LMWHs.</li>
                    </ul>
                    <h4>Primary Uses:</h4>
                    <p>LMWHs and fondaparinux are most commonly prescribed to prevent DVT and acute PE, particularly after:</p>
                    <ul>
                        <li>Orthopedic surgery (e.g., hip and knee replacement often use enoxaparin).</li>
                        <li>Abdominal surgery (e.g., dalteparin).</li>
                    </ul>
                    <h4>Administration:</h4>
                    <ul>
                        <li>Administered subcutaneously once or twice a day, depending on the drug.</li>
                        <li>Available in prefilled syringes with attached needles, making them convenient for self-administration.</li>
                        <li>Can be administered at home because aPTT monitoring is not necessary (unlike unfractionated heparin, which usually requires hospital administration).</li>
                        <li>Patients or family members are taught how to give subcutaneous injections, usually in the abdomen, alternating injection sites with every dose.</li>
                        <li>Average treatment period is 7 to 10 days, often started within 24 hours after surgery.</li>
                    </ul>
                    <h4>Precautions & Contraindications:</h4>
                    <ul>
                        <li>Patients should be instructed **not to take antiplatelet drugs such as aspirin** while taking LMWHs or heparin.</li>
                        <li>**Overdose is rare.** If bleeding occurs, protamine sulfate is the anticoagulant antagonist used (1 mg protamine for every 100 units of LMWH).</li>
                        <li>LMWHs are contraindicated for patients with:
                            <ul>
                                <li>Strokes (especially hemorrhagic strokes).</li>
                                <li>Peptic ulcers (due to bleeding risk).</li>
                                <li>Blood anomalies (e.g., thrombocytopenia).</li>
                                <li>Patients having eye, brain, or spinal surgery (high risk of catastrophic bleeding).</li>
                            </ul>
                        </li>
                    </ul>
                </div>
            </div>
            <div class="recap">
                <h4>Recap: LMWHs</h4>
                <ul>
                    <li>Derivatives of heparin, more stable, lower bleeding risk.</li>
                    <li>Primarily inactivate Factor Xa.</li>
                    <li>**NO aPTT monitoring needed.**</li>
                    <li>**Examples:** Enoxaparin, Dalteparin.</li>
                    <li>Fondaparinux: Selective Factor Xa inhibitor, synthetic, once-daily subcut.</li>
                    <li>**Uses:** DVT/PE prophylaxis post-ortho/abdominal surgery. Can be given at home.</li>
                    <li>**Longer half-life than heparin.**</li>
                    <li>**Cautions:** Avoid aspirin. Contraindicated in stroke, peptic ulcers, blood anomalies, eye/brain/spinal surgery.</li>
                    <li>**Antidote:** Protamine sulfate (if needed).</li>
                </ul>
            </div>
        </section>

        <section id="dtis">
            <h2>6. Direct Thrombin Inhibitors (DTIs): Parenteral Anticoagulants II</h2>
            <div class="info-card">
                <p>Direct Thrombin Inhibitors (DTIs) are a class of anticoagulants that work by directly inhibiting the activity of thrombin, a key enzyme in the coagulation cascade. This differs from heparin, which works indirectly through antithrombin III.</p>
                <button class="reveal-button">Explore Direct Thrombin Inhibitors</button>
                <div class="reveal-content">
                    <h4>Mechanism of Action:</h4>
                    <ul>
                        <li>Unlike heparin, these drugs **directly bind to and inhibit thrombin**, preventing it from converting fibrinogen to fibrin and promoting clot formation.</li>
                    </ul>
                    <h4>Parenteral DTIs (Administered Intravenously or Subcutaneously):</h4>
                    <ul>
                        <li><span class="highlight"><strong>Argatroban:</strong></span> Given intravenously. Primarily used for percutaneous coronary intervention (PCI) and in patients with heparin-induced thrombocytopenia (HIT).</li>
                        <li><span class="highlight"><strong>Bivalirudin:</strong></span> Given intravenously. Binds with and inhibits free-flowing thrombin. Used for thrombosis prophylaxis in PCI, unstable angina, and HIT.</li>
                        <li><span class="highlight"><strong>Desirudin:</strong></span> Administered subcutaneously. Used for DVT prophylaxis.</li>
                    </ul>
                    <h4>Oral DTI:</h4>
                    <ul>
                        <li><span class="highlight"><strong>Dabigatran:</strong></span> An oral anticoagulant that **does not require routine coagulation monitoring**, offering convenience compared to warfarin.</li>
                    </ul>
                    <div class="note">
                        <h4>Cost Consideration:</h4>
                        <p>These direct thrombin inhibitors are generally more expensive than older anticoagulants like heparin or warfarin.</p>
                    </div>
                </div>
            </div>
            <div class="recap">
                <h4>Recap: Direct Thrombin Inhibitors</h4>
                <ul>
                    <li>Directly inhibit thrombin.</li>
                    <li>**Parenteral:** Argatroban, Bivalirudin (IV, for PCI, HIT); Desirudin (subcut).</li>
                    <li>**Oral:** Dabigatran (no routine monitoring needed).</li>
                    <li>Generally more expensive.</li>
                </ul>
            </div>
        </section>

        <section id="oral-anticoagulants">
            <h2>7. Oral Anticoagulants: The Long-Term Players</h2>
            <div class="info-card">
                <p>Oral anticoagulants are crucial for long-term management of conditions that put patients at risk for clot formation. Warfarin has been the traditional oral anticoagulant, though newer options exist.</p>
                <button class="reveal-button">Dive into Warfarin: Action, Monitoring, & Management</button>
                <div class="reveal-content">
                    <h3>Warfarin: The Vitamin K Antagonist</h3>
                    <h4>Mechanism of Action:</h4>
                    <ul>
                        <li>Warfarin inhibits the <span class="highlight"><strong>hepatic synthesis of vitamin K</strong></span>, which in turn affects the production of several key clotting factors: Factors II (prothrombin), VII, IX, and X, as well as anticoagulant proteins. This slows down the clotting cascade.</li>
                    </ul>
                    <h4>Uses:</h4>
                    <p>Warfarin is mainly used to prevent thromboembolic conditions such as:</p>
                    <ul>
                        <li>Thrombophlebitis</li>
                        <li>Pulmonary Embolism (PE)</li>
                        <li>Embolism formation caused by <span class="tooltip-container">atrial fibrillation<span class="tooltip-text">A common type of irregular heartbeat that can lead to blood clots, stroke, heart failure, and other heart-related complications.</span></span> (which can lead to stroke)</li>
                        <li>Prophylaxis of MI, unstable angina, and for patients with prosthetic heart valves or after percutaneous coronary intervention (PCI).</li>
                    </ul>
                    <h4>Monitoring Warfarin Therapy:</h4>
                    <ul>
                        <li>Oral anticoagulants prolong clotting time.</li>
                        <li>Historically monitored by the <span class="highlight"><strong>Prothrombin Time (PT)</strong></span>, a lab test measuring the time it takes blood to clot.</li>
                        <li>Today, the <span class="highlight"><strong>International Normalized Ratio (INR)</strong></span> is the most frequently used lab test to report PT results. The INR was developed to standardize PT results across different laboratories due to reagent variability.</li>
                        <li>**Normal INR:** 1.3 to 2.</li>
                        <li>**Therapeutic INR for most patients on warfarin:** 2 to 3.</li>
                        <li>**Desired INR for patients with mechanical heart valves or recurrent systemic embolism:** 2.5 to 3.5, but can be as high as 4.5.</li>
                        <li>INR monitoring is required at regular intervals for the duration of drug therapy.</li>
                    </ul>
                    <h4>Pharmacokinetics & Pharmacodynamics:</h4>
                    <ul>
                        <li><strong>Absorption:</strong> Well absorbed through the GI mucosa. Food may delay but not inhibit absorption.</li>
                        <li><strong>Half-life:</strong> Long (20 to 60 hours).</li>
                        <li><strong>Protein Binding:</strong> Highly protein bound (97%).</li>
                        <li><strong>Duration:</strong> Very long. Drug accumulation can occur due to long half-life and high protein binding.</li>
                        <li><strong>Onset of Action (PO):</strong> 24-72 hours. Full effect may take 5-7 days.</li>
                        <li>Metabolized to inactive metabolites by the liver, excreted in urine and bile. Kidney and liver disease can prolong its half-life.</li>
                        <li>**Important:** Warfarin crosses the placental barrier and is **NOT recommended during pregnancy** (unlike heparin).</li>
                    </ul>
                    <h4>Side Effects and Adverse Reactions:</h4>
                    <ul>
                        <li><span class="highlight"><strong>Bleeding (hemorrhage) is the major adverse effect.</strong></span></li>
                        <li>Patients must be monitored closely for signs of bleeding:
                            <ul>
                                <li>Petechiae (tiny red/purple spots)</li>
                                <li>Ecchymosis (bruising)</li>
                                <li>Purpura (larger purplish spots)</li>
                                <li>Tarry stools (melena - indicates GI bleeding)</li>
                                <li>Hematemesis (vomiting blood)</li>
                                <li>Hematuria (blood in urine)</li>
                                <li>Ocular hemorrhage (bleeding in the eye)</li>
                                <li>Intracranial or vaginal bleeding.</li>
                                <li>Other: Headache, alopecia, fever, weakness, priapism, bone fracture, hypotension, chest pain.</li>
                            </ul>
                        </li>
                        <li><strong>Life-threatening:</strong> Hemorrhage, purple-toe syndrome.</li>
                    </ul>
                    <h4>Drug Interactions:</h4>
                    <ul>
                        <li>Warfarin's high protein binding makes it highly susceptible to drug interactions.</li>
                        <li>**Drugs that increase warfarin's effect (leading to increased bleeding risk):** Aspirin, NSAIDs (nonsteroidal anti-inflammatory drugs), other anti-inflammatory drugs, sulfonamides, phenytoin, cimetidine, allopurinol, oral hypoglycemic drugs (for diabetes), amiodarone, metronidazole, miconazole, SSRIs, SNRIs, cephalosporins. These drugs can displace warfarin from its protein-binding sites, increasing free circulating drug.</li>
                        <li>**Drugs that decrease warfarin's effect:** Barbiturates, laxatives, phenytoin, estrogens, vitamins C and K, oral contraceptives, rifampin.</li>
                        <li>**Safer pain relief alternative:** Acetaminophen should be used instead of aspirin or NSAIDs for patients taking warfarin.</li>
                    </ul>
                    <h4>Antidote for Warfarin Overdose:</h4>
                    <ul>
                        <li>The antidote is <span class="highlight"><strong>vitamin K (Phytonadione)</strong></span>, but it takes 24 to 48 hours to be effective.</li>
                        <li>Usually a low dose of oral vitamin K is recommended for mild elevation of INR (e.g., INR of 5.5 without significant bleeding).</li>
                        <li>If excessive vitamin K is given, it may take 1 to 2 weeks before warfarin can be effective again.</li>
                        <li>For acute or severe bleeding, <span class="highlight"><strong>fresh frozen plasma (FFP)</strong></span> is indicated for rapid reversal of anticoagulant effects.</li>
                    </ul>
                </div>
            </div>
            <div class="recap">
                <h4>Recap: Oral Anticoagulants (Warfarin)</h4>
                <ul>
                    <li>Inhibits hepatic synthesis of Vitamin K-dependent clotting factors (II, VII, IX, X).</li>
                    <li>**Uses:** Prevent venous/arterial thromboembolism (PE, AFib-related stroke, prosthetic heart valves, DVT).</li>
                    <li>**Monitor:** PT/INR. **Therapeutic INR:** 2-3 (up to 3.5 for specific conditions).</li>
                    <li>**Pharmacokinetics:** Well-absorbed, long half-life (20-60h), highly protein-bound. **Crosses placenta.**</li>
                    <li>**Side Effects/Adverse:** **Major is bleeding/hemorrhage.** Watch for petechiae, ecchymosis, tarry stools, hematuria, etc.</li>
                    <li>**Drug Interactions:** Highly protein-bound drugs, aspirin/NSAIDs **increase bleeding**. Many others. Use Acetaminophen for pain.</li>
                    <li>**Antidote:** Vitamin K (slow), Fresh Frozen Plasma (rapid).</li>
                </ul>
            </div>
        </section>

        <section id="factor-xa-inhibitors">
            <h2>8. Factor Xa Inhibitors: Newer Oral Anticoagulants</h2>
            <div class="info-card">
                <p>Factor Xa inhibitors represent a newer class of oral anticoagulants that offer advantages like predictable dosing and often no need for routine coagulation monitoring, making them a popular alternative to warfarin.</p>
                <button class="reveal-button">Key Details on Factor Xa Inhibitors</button>
                <div class="reveal-content">
                    <h4>Mechanism of Action:</h4>
                    <ul>
                        <li>These drugs selectively block the activity of <span class="highlight"><strong>clotting factor Xa</strong></span>, a critical component in the coagulation cascade, thereby preventing clot formation.</li>
                    </ul>
                    <h4>Examples:</h4>
                    <ul>
                        <li><span class="highlight"><strong>Oral Factor Xa Inhibitors:</strong></span>
                            <ul>
                                <li>Rivaroxaban (Xarelto)</li>
                                <li>Apixaban (Eliquis)</li>
                                <li>Edoxaban (Savaysa)</li>
                                <li>Betrixaban (Bevyxxa)</li>
                            </ul>
                        </li>
                        <li><span class="highlight"><strong>Parenteral Factor Xa Inhibitor:</strong></span>
                            <ul>
                                <li>Fondaparinux (mentioned with LMWHs, given subcutaneously)</li>
                            </ul>
                        </li>
                    </ul>
                    <h4>Key Characteristics & Uses:</h4>
                    <ul>
                        <li>Generally administered **once or twice daily**.</li>
                        <li><span class="highlight"><strong>Do NOT require routine coagulation monitoring</strong></span> (e.g., PT/INR), which simplifies management for patients.</li>
                        <li>Approved for the prevention and treatment of DVT and PE.</li>
                        <li>Used for stroke prophylaxis in nonvalvular atrial fibrillation (riva**xa**ban, api**xa**ban, edo**xa**ban).</li>
                        <li>Betrixaban is specifically for venous thromboembolism prophylaxis.</li>
                    </ul>
                    <h4>Side Effects and Adverse Reactions:</h4>
                    <ul>
                        <li>The major adverse effect across this class is <span class="highlight"><strong>bleeding</strong></span> (GI bleeding, ocular hemorrhage, intracranial bleeding, hematuria, menorrhagia, epistaxis, hemoptysis, hematemesis).</li>
                        <li>Other side effects can include anemia, hypokalemia, infection, dizziness, confusion, headache, hematoma, abdominal and back pain, pruritus, dyspepsia.</li>
                    </ul>
                    <div class="focus-prompt">
                        <h4>Important Caution!</h4>
                        <p>Factor Xa inhibitors should generally **not be given to patients weighing less than 50 kg** because low body weight increases the risk for bleeding with these medications.</p>
                    </div>
                </div>
            </div>
            <div class="recap">
                <h4>Recap: Factor Xa Inhibitors</h4>
                <ul>
                    <li>Selectively block Factor Xa to prevent clots.</li>
                    <li>**Oral:** Rivaroxaban, Apixaban, Edoxaban, Betrixaban. **Parenteral:** Fondaparinux.</li>
                    <li>**No routine coagulation monitoring needed.**</li>
                    <li>**Uses:** DVT/PE prevention/treatment, stroke prophylaxis in nonvalvular AFib.</li>
                    <li>**Major adverse effect: Bleeding.**</li>
                    <li>**Caution:** Not for patients <50 kg (increased bleeding risk).</li>
                </ul>
            </div>
        </section>

        <section id="nursing-process-anticoag">
            <h2>9. Clinical Judgment [Nursing Process]—Anticoagulants: Warfarin and Heparin</h2>
            <div class="info-card">
                <p>Applying the nursing process to anticoagulant therapy, especially with high-alert medications like warfarin and heparin, is critical for patient safety and effective outcomes. Our core concept here is **Clotting**, specifically the prevention of excessive clotting while minimizing bleeding risk.</p>
                <button class="reveal-button">Your Nursing Superpowers: Assessment to Evaluation!</button>
                <div class="reveal-content">
                    <h3>Recognize Cues [Assessment]: What do you notice?</h3>
                    <ul>
                        <li><strong>Obtain a thorough history:</strong>
                            <ul>
                                <li>History of abnormal clotting or health problems affecting clotting (e.g., severe alcoholism, severe liver or renal disease).</li>
                                <li>**Contraindications for Warfarin:** Blood dyscrasias, peptic ulcer, cerebrovascular accident (CVA), hemophilia, severe hypertension, head trauma, aneurysm, psychosis. Use with caution in acute traumatic injury.</li>
                                <li>**Contraindications for Heparin:** HIT (Heparin-Induced Thrombocytopenia), hypersensitivity. Caution with peptic ulcer, liver/renal disease, hemophilia, DIC, diverticulitis, head trauma, asthma, aneurysm, endocarditis, thrombocytopenia, older adults, pregnancy, breastfeeding.</li>
                            </ul>
                        </li>
                        <li><strong>Gather a comprehensive drug history:</strong>
                            <ul>
                                <li>Include all prescription, over-the-counter (OTC) drugs, and **complementary and alternative therapies (herbal products!)**.</li>
                                <li>Report any probable drug-drug or drug-herb interactions. Warfarin is highly protein-bound, so other highly protein-bound drugs can displace it (increasing free warfarin and bleeding risk), or warfarin itself can displace others.</li>
                            </ul>
                        </li>
                        <li><strong>Lab Monitoring Baseline:</strong> Obtain a baseline PT or INR before warfarin is administered, and aPTT for heparin.</li>
                    </ul>

                    <h3>Analyze Cues and Prioritize Hypotheses [Patient Problems]: What's the biggest issue?</h3>
                    <p>The primary concerns and potential patient problems when administering anticoagulants are related to:</p>
                    <ul>
                        <li><strong>Bleeding:</strong> The most significant risk.</li>
                        <li><strong>Tissue injury:</strong> Can occur from thrombosis or from bleeding complications.</li>
                        <li><strong>Dehydration:</strong> Can affect drug concentration or exacerbate bleeding.</li>
                    </ul>

                    <h3>Generate Solutions [Planning]: What's the goal?</h3>
                    <ul>
                        <li>The patient will not have excessive bleeding.</li>
                        <li>The patient's clotting times (PT/INR for warfarin, aPTT for heparin) will remain within the desired therapeutic range.</li>
                    </ul>

                    <h3>Take Action [Nursing Interventions]: What do YOU do?</h3>
                    <ul>
                        <li><strong>Monitor vital signs:</strong> An increased pulse rate followed by a decreased systolic blood pressure can indicate a fluid volume deficit resulting from external or internal bleeding.</li>
                        <li><strong>Monitor laboratory tests:</strong>
                            <ul>
                                <li>For warfarin: Monitor PT or INR before administering the anticoagulant.
                                    <ul>
                                        <li>PT should be 1.25 to 2.5 times the control level.</li>
                                        <li>INR should be 2 to 3 for most patients.</li>
                                        <li>For patients with prosthetic heart valves, INR may be up to 3.5 (or higher as specified).</li>
                                    </ul>
                                </li>
                                <li>For heparin: Monitor activated partial thromboplastin time (aPTT) before administering.
                                    <ul>
                                        <li>Therapeutic aPTT range is typically 1.5 to 2.5 times the control, or 30-85 seconds.</li>
                                    </ul>
                                </li>
                                <li>Monitor platelet count regularly, as anticoagulants (especially heparin) can decrease it (leading to HIT).</li>
                            </ul>
                        </li>
                        <li><strong>Examine the patient for signs of bleeding:</strong> Check the mouth, nose (epistaxis), urine (hematuria), and skin (petechiae, purpura, ecchymosis). Pay close attention to older adults, whose thin skin and fragile capillary beds make them more susceptible to bleeding.</li>
                        <li><strong>Check stools periodically for occult blood</strong> (blood not visible to the naked eye).</li>
                        <li><strong>Keep anticoagulant antagonists available:</strong> Protamine sulfate for heparin and vitamin K (phytonadione) for warfarin, especially when the drug dose is increased or indications of frank bleeding are evident. Fresh frozen plasma (FFP) may be needed for transfusion in severe cases.</li>
                    </ul>

                    <h3>Patient Teaching: Empowering Your Patient!</h3>
                    <h4>General Advice:</h4>
                    <ul>
                        <li>Teach patients to inform their dentist or any other healthcare provider that they are taking an anticoagulant.</li>
                        <li>Advise patients to use a **soft toothbrush** to prevent gum bleeding.</li>
                        <li>Warn patients to shave with an **electric razor**. Bleeding from shaving cuts may be difficult to control.</li>
                        <li>Advise patients to have laboratory tests (PT or INR) performed as ordered. Emphasize that the warfarin dose is regulated precisely according to the INR.</li>
                        <li>Suggest that patients carry a **medical identification card or wear a MedicAlert bracelet** that lists their name, telephone number, and the anticoagulant drug taken.</li>
                        <li>Encourage patients **not to smoke**. Smoking increases drug metabolism, so the warfarin dose may need to be increased. If a patient insists on smoking, notify the healthcare provider.</li>
                        <li>Tell patients to **check with a healthcare provider before taking any over-the-counter (OTC) drugs**. Aspirin should not be taken with warfarin because it intensifies warfarin’s action and increases bleeding risk. Suggest that patients use acetaminophen (Tylenol) for pain.</li>
                        <li>Inform patients that many **herbal products interact with anticoagulants** and may increase bleeding or decrease effectiveness (see complementary and alternative therapies below). Closely monitor INR or PT if they insist on using them.</li>
                        <li>Teach patients to control external hemorrhage from accidents or injuries by applying firm, direct pressure for at least 5 to 10 minutes with a clean, dry, absorbent material.</li>
                    </ul>
                    <h4>Side Effects:</h4>
                    <ul>
                        <li>Warn patients to report any signs of frank or occult bleeding immediately: petechiae, ecchymosis, purpura, tarry stools, bleeding gums, epistaxis (nosebleeds), or expectoration of blood (hemoptysis).</li>
                    </ul>
                    <h4>Diet:</h4>
                    <ul>
                        <li>Advise patients to **avoid large amounts of green, leafy vegetables; broccoli; legumes; and soybean oil** (all rich in vitamin K) or to be very consistent with their intake. Sudden changes in vitamin K intake can destabilize INR.</li>
                        <li>Limit intake of caffeine (coffee, tea, cola) and excessive alcohol, as they can interact with warfarin.</li>
                        <li>Certain herbs and nutritional supplements can interact:
                            <ul>
                                <li>**May decrease effectiveness of warfarin:** Coenzyme Q10, fish oils, substances high in vitamin K, St. John’s wort, ginseng, vitamin C, alfalfa, goldenseal, valerian, green tea.</li>
                                <li>**May increase bleeding when taken with anticoagulants (additive effect with warfarin, increasing INR/PT):** Dong quai, feverfew, garlic, ginger, meadowsweet, willow bark, chamomile tea, ginkgo, bilberry, excessive doses of anise, hawthorn.</li>
                                <li>**May potentiate drug effects:** St. John's wort with clopidogrel (antiplatelet).</li>
                            </ul>
                        </li>
                    </ul>

                    <h3>Evaluate Outcomes [Evaluation]: Did it work?</h3>
                    <ul>
                        <li>Evaluate the effectiveness of drug therapy: Confirm that the patient’s PT or INR values (for warfarin) or aPTT values (for heparin) are within the desired therapeutic range.</li>
                        <li>Ensure the patient is free from significant side effects, especially signs of excessive bleeding.</li>
                        <li>Patient verbalizes understanding of drug regimen, precautions, and when to report symptoms.</li>
                    </ul>
                </div>
            </div>
            <div class="recap">
                <h4>Recap: NP - Anticoagulants (Warfarin & Heparin)</h4>
                <ul>
                    <li>**Concept:** Clotting. Goal: Prevent excessive clotting, minimize bleeding.</li>
                    <li>**Assess:** Clotting history, contraindications (CVA, ulcers, severe HTN for warfarin; HIT for heparin), ALL medications/herbs (interactions!). Baseline PT/INR/aPTT.</li>
                    <li>**Problems:** Bleeding (primary), tissue injury, dehydration.</li>
                    <li>**Plan:** No excessive bleeding. Labs in therapeutic range.</li>
                    <li>**Intervene:** Monitor VS (HR up, BP down = bleeding), labs (PT/INR/aPTT, platelets), inspect for bleeding (mouth, nose, urine, skin, occult stools). Keep antagonists (Protamine, Vit K, FFP) ready.</li>
                    <li>**Teach:** Inform all providers, soft toothbrush, electric razor, regular labs, MedicAlert. **NO smoking, NO aspirin/NSAIDs (use acetaminophen).** **Watch herbal interactions!** Direct pressure for external bleeding. Report ANY bleeding (petechiae, tarry stools, hematuria, etc.). Diet: consistent Vit K intake.</li>
                    <li>**Evaluate:** Labs in range, no significant bleeding, patient understanding.</li>
                </ul>
            </div>
        </section>

        <section id="anticoagulant-antagonists">
            <h2>10. Anticoagulant Antagonists: Reversing the Effects</h2>
            <div class="info-card">
                <p>When anticoagulation becomes excessive, leading to dangerous bleeding, specific antagonists are used to reverse their effects.</p>
                <button class="reveal-button">Know Your Antidotes!</button>
                <div class="reveal-content">
                    <ul>
                        <li><span class="highlight"><strong>Protamine Sulfate:</strong></span>
                            <ul>
                                <li>**Antidote for:** Heparin and Low-Molecular-Weight Heparins (LMWHs).</li>
                                <li>**Mechanism:** A protein that acts as an anticoagulant itself but, in the presence of heparin/LMWH, binds to it and inactivates it.</li>
                                <li>**Dosage:** Typically 1 mg for every 100 units of unfractionated heparin to be neutralized.</li>
                                <li>**Side Effects:** Hypotension, flushing, bradycardia, fatigue, pulmonary edema, dyspnea.</li>
                            </ul>
                        </li>
                        <li><span class="highlight"><strong>Phytonadione (Vitamin K1):</strong></span>
                            <ul>
                                <li>**Antidote for:** Warfarin overdose or uncontrollable bleeding.</li>
                                <li>**Mechanism:** Vitamin K is essential for the hepatic synthesis of clotting factors that warfarin inhibits. Providing exogenous Vitamin K allows the liver to produce these factors.</li>
                                <li>**Administration:** Usually 5 to 10 mg given by slow intravenous infusion. Oral doses may be used for less severe INR elevation.</li>
                                <li>**Onset:** Takes 24 to 48 hours to be effective, as the liver needs time to synthesize new clotting factors.</li>
                                <li>**Caution:** Excessive vitamin K can make warfarin ineffective for 1 to 2 weeks afterwards.</li>
                                <li>**Side Effects:** Anaphylaxis, dizziness, flushing, dysgeusia (taste disturbance), dyspnea, hyperhidrosis (excessive sweating), tachycardia, hypotension.</li>
                            </ul>
                        </li>
                        <li><span class="highlight"><strong>Fresh Frozen Plasma (FFP) or Whole Blood:</strong></span>
                            <ul>
                                <li>**Antidote for:** Acute, severe bleeding from warfarin or heparin overdose when rapid reversal is critical, especially while waiting for vitamin K to take effect or if vitamin K is insufficient.</li>
                                <li>**Mechanism:** Provides immediate replacement of clotting factors.</li>
                            </ul>
                        </li>
                    </ul>
                </div>
            </div>
            <div class="recap">
                <h4>Recap: Anticoagulant Antagonists</h4>
                <ul>
                    <li>**Protamine Sulfate:** For Heparin and LMWHs.</li>
                    <li>**Phytonadione (Vitamin K1):** For Warfarin. Slow onset (24-48h).</li>
                    <li>**Fresh Frozen Plasma (FFP):** For rapid reversal of severe bleeding from warfarin or heparin.</li>
                </ul>
            </div>
        </section>

        <section id="antiplatelet-drugs">
            <h2>11. Antiplatelet Drugs: Stopping Platelet Clumping</h2>
            <div class="info-card">
                <p><span class="tooltip-container">Antiplatelet drugs<span class="tooltip-text">Medications that prevent platelets from clumping together (aggregating), thereby inhibiting the formation of arterial clots.</span></span> are used to prevent thrombosis primarily in the arteries by suppressing platelet aggregation (clumping). Remember, heparin and warfarin mainly prevent thrombosis in the veins.</p>
                <button class="reveal-button">Antiplatelets: Uses, Examples, & Interactions</button>
                <div class="reveal-content">
                    <h4>Primary Uses (Prophylactic):</h4>
                    <ul>
                        <li>Prevention of <span class="highlight"><strong>MI (myocardial infarction) or stroke</strong></span> for patients with a family history of these conditions.</li>
                        <li>Prevention of a <span class="highlight"><strong>repeat MI or stroke</strong></span> (secondary prevention).</li>
                        <li>Prevention of stroke for patients having <span class="tooltip-container">transient ischemic attacks (TIAs)<span class="tooltip-text">A "mini-stroke" that causes stroke-like symptoms but no lasting damage. It's a warning sign of a future stroke.</span></span>.</li>
                    </ul>
                    <h3>Key Antiplatelet Drugs:</h3>
                    <h4>1. Aspirin (ASA): The Old Reliable</h4>
                    <ul>
                        <li><strong>Mechanism:</strong> Inhibits <span class="highlight"><strong>cyclooxygenase (COX)</strong></span>, an enzyme necessary for platelets to synthesize thromboxane A2 (TxA2). This prevents platelet activation and aggregation.</li>
                        <li><strong>Long-term, low-dose aspirin therapy</strong> is effective and inexpensive for suppressing platelet aggregation.</li>
                        <li><strong>Recommended Doses:</strong>
                            <ul>
                                <li>Stroke prophylaxis: 50 to 325 mg/day.</li>
                                <li>MI prophylaxis: 75 to 162 mg/day.</li>
                            </ul>
                        </li>
                        <li><strong>Important Precaution:</strong> Aspirin has prolonged antiplatelet activity. It should be **discontinued at least 7 days before surgery** to reduce bleeding risk.</li>
                        <li><strong>Side Effects:</strong> Abdominal pain, nausea, dyspepsia, gastritis, GI bleeding, intracranial bleeding, epistaxis.</li>
                    </ul>
                    <h4>2. Adenosine Diphosphate (ADP) Antagonists:</h4>
                    <ul>
                        <li>These drugs affect platelet aggregation by blocking ADP from binding with the ADP platelet receptor, inhibiting activation of the GP IIb/IIIa complex.</li>
                        <li><span class="highlight"><strong>Clopidogrel (Plavix):</strong></span>
                            <ul>
                                <li>Frequently used after MI or stroke to prevent a second event.</li>
                                <li>May be prescribed alone or with aspirin (often more effective together).</li>
                                <li><strong>Pharmacokinetics:</strong> Rapidly absorbed, high protein binding (94%-98%), half-life 6 hours. Excreted equally in urine and feces.</li>
                                <li><strong>Precautions:</strong> Should be discontinued 7 days preceding surgery. Not taken if active bleeding (peptic ulcer, intracranial hemorrhage).</li>
                                <li><strong>Side Effects:</strong> Abdominal pain, dizziness, headaches, hematoma, dyspepsia, diarrhea, rash, pruritus, purpura, peripheral edema.</li>
                                <li><strong>Adverse/Life-threatening:</strong> Hypotension, hypertension, bronchospasm, bleeding (including peptic ulcer, intracranial/GI), agranulocytosis, aplastic anemia, thrombocytopenia, pancytopenia, hepatic failure, Stevens-Johnson syndrome.</li>
                            </ul>
                        </li>
                        <li><span class="highlight"><strong>Prasugrel:</strong></span> Used for thromboembolism prophylaxis. Higher risk of bleeding than clopidogrel.</li>
                        <li><span class="highlight"><strong>Ticagrelor:</strong></span> Often taken with low-dose aspirin (75-100mg) for thromboembolism prophylaxis. Doses >100mg of aspirin should be avoided with ticagrelor.</li>
                        <li><span class="highlight"><strong>Dipyridamole:</strong></span> Can be used alone or in combination with warfarin (for prosthetic heart valves) or aspirin (for stroke prevention).</li>
                    </ul>
                    <h4>3. Phosphodiesterase III Inhibitors:</h4>
                    <ul>
                        <li><span class="highlight"><strong>Cilostazol:</strong></span> Inhibits platelet aggregation AND is a vasodilator. Used for <span class="tooltip-container">intermittent claudication<span class="tooltip-text">Cramping pain in the leg that is induced by exercise, typically caused by obstruction of the arteries.</span></span> (pain in legs due to poor circulation). Smoking may decrease its serum levels.</li>
                    </ul>
                    <h4>4. Protease-Activated Receptor-1 (PAR-1) Antagonists:</h4>
                    <ul>
                        <li><span class="highlight"><strong>Vorapaxar:</strong></span> For prevention of thrombosis, MI, peripheral artery disease (PAD), and stroke. Used in combination with aspirin and/or clopidogrel. High bleeding risk.</li>
                    </ul>
                    <h4>5. Glycoprotein (GP) IIb/IIIa Receptor Antagonists: The "Super Aspirins"</h4>
                    <ul>
                        <li>These are potent antiplatelets given intravenously. They block the binding of fibrinogen to the GP IIb/IIIa receptor on the platelet surface, preventing platelet aggregation.</li>
                        <li>Used primarily for <span class="highlight"><strong>acute coronary syndromes</strong></span> (unstable angina or non-Q-wave MI) and for preventing reocclusion of coronary arteries after percutaneous transluminal coronary angioplasty (PTCA).</li>
                        <li>Examples:
                            <ul>
                                <li><span class="highlight"><strong>Abciximab:</strong></span> Often the drug of choice for angioplasty. Antiplatelet effects persist up to 10 days after IV infusion.</li>
                                <li><span class="highlight"><strong>Eptifibatide:</strong></span> Antiplatelet effects last for ~4 hours.</li>
                                <li><span class="highlight"><strong>Tirofiban:</strong></span> Antiplatelet effects last for ~4 hours.</li>
                            </ul>
                        </li>
                    </ul>
                    <h4>6. Other Antiplatelets & Combinations:</h4>
                    <ul>
                        <li><span class="highlight"><strong>Cangrelor:</strong></span> IV only, for prevention of thrombosis in PCI and MI. Very rapid onset/offset.</li>
                        <li><strong>Combination drugs:</strong>
                            <ul>
                                <li>Dipyridamole (extended release) + Aspirin: For stroke prevention (ischemic stroke and TIA).</li>
                                <li>Aspirin + Omeprazole: For prophylaxis of secondary cardiovascular/cerebrovascular events, with gastric protection.</li>
                            </ul>
                        </li>
                    </ul>
                    <div class="complementary-alternative-therapy note">
                        <h4>Complementary and Alternative Therapies & Antiplatelets:</h4>
                        <p>Many herbal products can interfere with platelet aggregation and increase bleeding risk when taken with antiplatelet drugs:</p>
                        <ul>
                            <li><strong>Increase bleeding:</strong> Dong quai, feverfew, garlic, ginger, Korean ginseng, saw palmetto, ginkgo biloba.</li>
                            <li><strong>May potentiate drug effects:</strong> St. John’s wort with clopidogrel.</li>
                            <li><strong>Other interactions:</strong> Licorice (may cause hypokalemia, potentiating drug toxicity).</li>
                        </ul>
                    </div>
                </div>
            </div>
            <div class="recap">
                <h4>Recap: Antiplatelet Drugs</h4>
                <ul>
                    <li>Prevent **arterial thrombosis** by suppressing platelet aggregation.</li>
                    <li>**Uses:** Prophylaxis MI/stroke (primary/secondary), TIA.</li>
                    <li>**Aspirin:** Inhibits COX/TxA2. Discontinue 7 days before surgery.</li>
                    <li>**ADP Antagonists:** Clopidogrel (Plavix), Prasugrel, Ticagrelor. Block ADP binding. Clopidogrel: monitor for bleeding, thrombocytopenia, SJS.</li>
                    <li>**Other Oral:** Cilostazol (claudication, vasodilator), Vorapaxar.</li>
                    <li>**GP IIb/IIIa Antagonists (IV):** Abciximab, Eptifibatide, Tirofiban. Potent, for acute coronary syndromes/PCI.</li>
                    <li>**Herbal Interactions:** Many herbs (garlic, ginger, ginkgo, etc.) increase bleeding risk.</li>
                </ul>
            </div>
        </section>

        <section id="thrombolytics">
            <h2>12. Thrombolytics: The Clot Busters!</h2>
            <div class="info-card">
                <p><span class="tooltip-container">Thromboembolism<span class="tooltip-text">Occlusion of a blood vessel by a thrombus (blood clot) or embolus (traveling clot), leading to ischemia (deficient blood flow) and potentially tissue necrosis.</span></span> (a blocked artery or vein by a clot) causes <span class="highlight">ischemia</span> and eventually <span class="tooltip-container">necrosis<span class="tooltip-text">The death of body tissue due to lack of blood flow or other injury.</span></span> (tissue death) if not resolved. While the body has natural mechanisms to break down clots (fibrinolysis) over 1-2 weeks, thrombolytic drugs accelerate this process to minimize tissue damage.</p>
                <button class="reveal-button">Thrombolytics: Action, Uses, & Crucial Timing</button>
                <div class="reveal-content">
                    <h4>Mechanism of Action:</h4>
                    <ul>
                        <li>Thrombolytics promote the <span class="highlight"><strong>fibrinolytic mechanism</strong></span>. They work by converting <span class="highlight"><strong>plasminogen to plasmin</strong></span>.</li>
                        <li><span class="highlight"><strong>Plasmin</strong></span> is an enzyme that directly attacks and digests the <span class="highlight"><strong>fibrin</strong></span> in the blood clot, causing the thrombus to disintegrate.</li>
                        <li>Plasmin also degrades other clotting factors like fibrinogen, prothrombin, and factors V, VIII, and XII.</li>
                        <li>These drugs all induce fibrinolysis (fibrin breakdown).</li>
                    </ul>
                    <h4>Crucial Administration Timing:</h4>
                    <p>The effectiveness of thrombolytics is highly time-dependent. The earlier they are administered after symptom onset, the greater the benefit.</p>
                    <ul>
                        <li><strong>Acute Myocardial Infarction (AMI):</strong> Ideally administered within **3 to 4 hours** of symptom onset, or within **30 minutes** of arrival at the hospital. Benefits may still be seen up to 12 hours.</li>
                        <li><strong>Thrombotic Stroke (Ischemic Stroke):</strong> Should be administered within **3 hours** of symptom onset (some guidelines extend this to 4.5 hours for select patients).</li>
                    </ul>
                    <p>Rapid dissolution of the clot minimizes tissue necrosis and reestablishes blood flow, potentially reducing hospitalization time and avoiding invasive procedures like cardiac bypass or angioplasty.</p>
                    <h4>Key Uses:</h4>
                    <ul>
                        <li>Acute Myocardial Infarction (AMI)</li>
                        <li>Ischemic Stroke (Thrombotic Stroke)</li>
                        <li>Pulmonary Embolism (PE)</li>
                        <li>Deep Vein Thrombosis (DVT)</li>
                        <li>Noncoronary arterial occlusion from an acute thromboembolism</li>
                        <li>Occluded IV catheters (e.g., central lines, often with a smaller dose)</li>
                    </ul>
                    <h4>Commonly Used Thrombolytics:</h4>
                    <ul>
                        <li><span class="highlight"><strong>Alteplase (Activase, also known as tissue plasminogen activator - tPA):</strong></span>
                            <ul>
                                <li>**Mechanism:** Clot-specific; binds to the fibrin surface of a clot, promoting the conversion of plasminogen to plasmin. It is identical to natural human tPA.</li>
                                <li>**Administration (AMI/PE):** 100 mg infusion over 2 hours.</li>
                                <li>**Administration (Ischemic CVA):** 0.9 mg/kg (10% as bolus over 1 min, then 90% as infusion over 1 hour), max 90mg. Administered within 3 hours of symptom onset.</li>
                                <li>Allergic reactions occur less frequently than with other thrombolytics.</li>
                                <li>**Pharmacokinetics:** Half-life is 30 minutes. Peak action 5-10 min. Duration 1 hour.</li>
                                <li>**Side Effects:** Epistaxis, infection, ecchymosis, nausea, vomiting, rash.</li>
                                <li>**Adverse/Life-threatening:** Anaphylactoid reactions (rash, laryngeal edema, angioedema, shock), cholesterol microembolization, **bleeding (major complication)**, hypo/hypertension, GI bleeding, MI, cerebral edema, rhabdomyolysis, bradycardia, tachycardia, heart failure, intracranial hemorrhage, seizures, dysrhythmias, pulmonary edema, renal failure.</li>
                            </ul>
                        </li>
                        <li><span class="highlight"><strong>Tenecteplase (TNK tPA):</strong></span>
                            <ul>
                                <li>**Administration:** 30–50 mg bolus over 5 seconds; administer within 30 min of hospital arrival for AMI.</li>
                                <li>May cause bleeding, stroke, hematoma, epistaxis, GI bleeding. Anaphylaxis in <1% of patients.</li>
                                <li>Half-life: 90-130 minutes.</li>
                            </ul>
                        </li>
                        <li><span class="highlight"><strong>Reteplase (r-PA):</strong></span>
                            <ul>
                                <li>**Administration:** 10 units over 2 min, followed in 30 min with second 10 units for AMI.</li>
                                <li>Penetrates clots and activates plasminogen inside the clot, potentially leading to higher clot lysis rate.</li>
                                <li>May cause bleeding (GI/intracranial), purple-toe syndrome.</li>
                                <li>Half-life: 13-16 minutes.</li>
                            </ul>
                        </li>
                    </ul>
                    <div class="focus-prompt">
                        <h4>Critical Caution: Drug Interactions!</h4>
                        <p>Anticoagulants and antiplatelet drugs significantly increase the risk of hemorrhage when combined with thrombolytics. They should generally be **avoided until the thrombolytic effect has passed.** Always determine if a patient has taken any of these drugs before starting thrombolytic treatment!</p>
                    </div>
                    <h4>Antithrombotic Antidote for Thrombolytic-Induced Bleeding:</h4>
                    <ul>
                        <li><span class="highlight"><strong>Aminocaproic acid (Amicar):</strong></span> Used to stop bleeding by inhibiting plasminogen activation, thereby inhibiting thrombolysis.</li>
                    </ul>
                </div>
            </div>
            <div class="recap">
                <h4>Recap: Thrombolytics</h4>
                <ul>
                    <li>**"Clot Busters"** – dissolve existing clots.</li>
                    <li>**Mechanism:** Convert plasminogen to plasmin, which degrades fibrin in clots.</li>
                    <li>**CRUCIAL TIMING:** AMI (within 3-4h or 30min hosp arrival), Ischemic Stroke (within 3h).</li>
                    <li>**Uses:** AMI, Ischemic Stroke, PE, DVT, occluded IV catheters.</li>
                    <li>**Examples:** Alteplase (tPA), Tenecteplase, Reteplase.</li>
                    <li>**MAJOR COMPLICATION: HEMORRHAGE.**</li>
                    <li>**Antidote for bleeding:** Aminocaproic acid.</li>
                    <li>**Avoid** anticoagulants/antiplatelets during thrombolytic therapy (high bleeding risk!).</li>
                </ul>
            </div>
        </section>

        <section id="nursing-process-thrombolytics">
            <h2>13. Clinical Judgment [Nursing Process]—Thrombolytics</h2>
            <div class="info-card">
                <p>Administering thrombolytics is a high-stakes nursing responsibility due to their potent effects and the significant risk of hemorrhage. Our core concept remains **Clotting**, specifically managing its reversal.</p>
                <button class="reveal-button">Your Nursing Superpowers: Assessment to Evaluation for Thrombolytics!</button>
                <div class="reveal-content">
                    <h3>Recognize Cues [Assessment]: What do you notice?</h3>
                    <ul>
                        <li><strong>Assess baseline vital signs</strong> for comparison throughout therapy.</li>
                        <li><strong>Check baseline complete blood count (CBC), prothrombin time (PT), or international normalized ratio (INR) values</strong> before administration.</li>
                        <li><strong>Obtain a comprehensive medical and drug history:</strong>
                            <ul>
                                <li>**Absolute Contraindications:** Recent cerebrovascular accident (CVA, especially hemorrhagic), active bleeding, severe uncontrolled hypertension, intracranial bleeding/aneurysm/brain tumor/head trauma, thrombocytopenia, coagulopathy.</li>
                                <li>**Relative Contraindications/Caution:** Atrial fibrillation, hepatic/renal disease, recent CABG (coronary artery bypass graft) surgery, peptic ulcer disease, diabetic retinopathy, older adults, pregnancy.</li>
                                <li>Report if the patient takes aspirin or nonsteroidal anti-inflammatory drugs (NSAIDs) – these greatly increase bleeding risk.</li>
                                <li>**Crucial:** Recent history of traumatic injury, especially head injury, is an absolute contraindication.</li>
                            </ul>
                        </li>
                    </ul>

                    <h3>Analyze Cues and Prioritize Hypotheses [Patient Problems]: What's the biggest issue?</h3>
                    <p>The primary concerns and potential patient problems when administering thrombolytics are:</p>
                    <ul>
                        <li><strong>Bleeding:</strong> The most critical risk.</li>
                        <li><strong>Tissue injury:</strong> Could be from the initial clot or complications of therapy.</li>
                        <li><strong>Dehydration:</strong> Can affect drug concentration or patient stability.</li>
                    </ul>

                    <h3>Generate Solutions [Planning]: What's the goal?</h3>
                    <ul>
                        <li>The patient’s vital signs will be within normal limits.</li>
                        <li>The patient will be free of excessive bleeding.</li>
                        <li>The blood clot will be dissolved, restoring blood flow.</li>
                        <li>The patient will be pain-free (if initial pain was clot-related).</li>
                    </ul>

                    <h3>Take Action [Nursing Interventions]: What do YOU do?</h3>
                    <ul>
                        <li><strong>Monitor vital signs meticulously:</strong> An increased pulse rate followed by decreased blood pressure usually indicates blood loss and impending shock. Record vital signs frequently (e.g., every 15 minutes initially), and report changes immediately.</li>
                        <li><strong>Observe for signs and symptoms of active bleeding:</strong> From the mouth, rectum, or any other site (IV insertion points, surgical sites). Hemorrhage is the most serious complication.</li>
                        <li>**Examine the patient for active bleeding for 24 hours after thrombolytic therapy:** This should be done extremely frequently initially (e.g., every 15 minutes for the first hour, then every 30 minutes until the eighth hour, and then hourly) per protocol.</li>
                        <li>Keep **aminocaproic acid** (antidote) readily available as an intervention to stop bleeding if severe hemorrhage occurs.</li>
                        <li><strong>Observe for signs of allergic reaction to thrombolytics:</strong> Such as itching, hives, flushing, fever, dyspnea, bronchospasm, hypotension, and/or cardiovascular collapse.</li>
                        <li>**Avoid administering aspirin or NSAIDs** for pain or discomfort when the patient is receiving a thrombolytic, as they significantly increase bleeding risk. Acetaminophen can be substituted.</li>
                        <li><strong>Monitor the electrocardiogram (ECG)</strong> for the presence of **reperfusion dysrhythmias** as the blood clot dissolves. Antidysrhythmic therapy may be indicated.</li>
                        <li><strong>Avoid venipuncture/arterial sticks</strong> as much as possible to minimize bleeding sites. If necessary, apply prolonged pressure after.</li>
                        <li>**Maintain strict bed rest** and limit patient movement to prevent bleeding from dislodged clots or existing puncture sites.</li>
                    </ul>

                    <h3>Patient Teaching: Empowering Your Patient!</h3>
                    <h4>General Advice:</h4>
                    <ul>
                        <li>Explain thrombolytic treatment to patients and family members in clear, simple terms. Provide emotional support, as this can be a frightening experience.</li>
                        <li>Emphasize the critical nature of the immediate treatment and the close monitoring.</li>
                        <li>Instruct patient and family to report any signs of bleeding immediately.</li>
                    </ul>
                    <h4>Side Effects:</h4>
                    <ul>
                        <li>Advise patients to report any uncomfortable side effects such as lightheadedness, dizziness, palpitations, nausea, pruritus (itching), or urticaria (hives).</li>
                    </ul>

                    <h3>Evaluate Outcomes [Evaluation]: Did it work?</h3>
                    <ul>
                        <li>Determine the effectiveness of drug therapy: Assess if the clot has dissolved, vital signs are stable, and the patient is free from signs or symptoms of active bleeding.</li>
                        <li>Confirm the patient is pain-free (if pain was related to the clot).</li>
                        <li>Monitor for return of blood flow to the affected area (e.g., resolution of chest pain, improved neurological status in stroke).</li>
                    </ul>
                </div>
            </div>
            <div class="recap">
                <h4>Recap: NP - Thrombolytics</h4>
                <ul>
                    <li>**Concept:** Clotting. Goal: Reverse clotting, manage bleeding.</li>
                    <li>**Assess:** Baseline VS, CBC, PT/INR. **CRITICAL:** Medical/drug history for contraindications (recent CVA, active bleeding, severe HTN, head trauma, aspirin/NSAIDs use).</li>
                    <li>**Problems:** Bleeding (primary), tissue injury, dehydration.</li>
                    <li>**Plan:** Stable VS, no excessive bleeding, clot dissolved, pain free.</li>
                    <li>**Intervene:** **Frequent VS monitoring (pulse up, BP down = bleeding/shock!)**, observe for ALL bleeding (24h post-therapy), keep Aminocaproic acid ready. **NO aspirin/NSAIDs.** Monitor ECG (reperfusion dysrhythmias). **AVOID venipuncture/arterial sticks.** Strict bed rest.</li>
                    <li>**Teach:** Explain treatment, report ANY side effects or bleeding.</li>
                    <li>**Evaluate:** Clot dissolved, stable VS, no active bleeding, pain free.</li>
                </ul>
            </div>
        </section>

        <section id="case-study" class="nclex-next-gen">
            <h3>14. Critical Thinking Case Study: Thrombophlebitis to Warfarin Therapy</h3>
            <p class="case-study">A 57-year-old man has thrombophlebitis in the right lower leg. IV heparin, 5000 units by bolus, was given. After the IV bolus, heparin 5000 units given subcutaneously every 6 hours was prescribed. Other therapeutic means to decrease pain and alleviate swelling and redness were also prescribed, and an aPTT test was ordered.</p>

            <div class="fill-in-the-blank">
                <p>1. Was the patient’s heparin order within the safe daily dosage range? Explain your answer.</p>
                <textarea id="cs_q1_text" placeholder="Type your answer here."></textarea>
                <button class="submit-btn" id="submit_cs_q1_text">Check My Answer!</button>
                <div class="feedback" id="cs_q1_text_feedback"></div>
                <div class="rationale" id="cs_q1_text_rationale">
                    <h4>Rationale: Why this answer is correct!</h4>
                    <p><strong>ANS:</strong> The patient's heparin order was **not within a typical safe daily dosage range for *acute thrombosis treatment* if it's the *only* dose. However, the scenario describes both an initial IV bolus AND subsequent subcutaneous doses. For DVT/PE treatment, the typical adult IV bolus is 80 units/kg, followed by an 18 units/kg/hr continuous infusion based on aPTT. Subcutaneous heparin for prophylaxis (e.g., DVT prevention) is usually 5,000 units q8-12h. For *treatment* of established thrombosis, subcutaneous doses are often higher or administered more frequently (e.g., 5000 units q6h might be a bit low for initial *treatment* but could be within a range for prophylaxis or maintenance after initial treatment). Given the information "IV heparin, 5000 units by bolus, was given. After the IV bolus, heparin 5000 units given subcutaneously every 6 hours was prescribed", it suggests the subcutaneous regimen is for *continued* anticoagulation. A daily subcutaneous dose of 5,000 units every 6 hours would be 20,000 units/day. This could be a prophylactic or low-treatment dose. It's on the lower side for full acute treatment, which is typically continuous IV. Without the patient's weight, it's hard to assess the 80 units/kg bolus accurately, but 5000 units is a standard flat dose. It's safe in the sense it's not immediately life-threatening overdose, but its *therapeutic efficacy* for treatment might be questioned if not followed by a higher IV or dose-adjusted subcutaneous regimen. **For exam purposes, the provided text's "DVT or PE: A: IV: 80 units/kg bolus; maint: 18 units/kg/h infusion based on aPTT" suggests a continuous IV is the *main treatment*. The 5000 units subcut q6h may be a lower, prophylactic-like dose, or a very specific treatment regimen. Therefore, stating it's on the "lower side for acute treatment" or "typical for prophylaxis" is appropriate.**</p>
                    <p>Let's consider the initial 5000 units IV bolus as a starting dose and the subsequent 5000 units subcutaneously every 6 hours. This adds up to 20,000 units per day. This dosage regimen is common for prophylaxis of DVT or for treating less severe cases, or as a bridge therapy. However, for established thrombophlebitis that requires active treatment (rather than just prevention), a continuous intravenous infusion of heparin, adjusted by aPTT, is often preferred for more consistent therapeutic levels. The bolus of 5000 units is a standard initial dose. The subcutaneous regimen of 5000 units every 6 hours (20,000 units/day) is a common prophylactic dose, but can also be a treatment dose depending on the patient and severity. It is within a safe *daily* range for heparin (max can be 40,000-60,000 units/day, though rarely given this high). However, for *treatment*, continuous IV infusion is generally preferred for therapeutic levels. So, yes, it's generally within a "safe" range, but the efficacy for *treating* active thrombophlebitis might be better with IV continuous infusion.</p>
                </div>
            </div>

            <div class="fill-in-the-blank">
                <p>2. What are the various methods for administering heparin?</p>
                <textarea id="cs_q2_text" placeholder="Type your answer here."></textarea>
                <button class="submit-btn" id="submit_cs_q2_text">Check My Answer!</button>
                <div class="feedback" id="cs_q2_text_feedback"></div>
                <div class="rationale" id="cs_q2_text_rationale">
                    <h4>Rationale: Why this answer is correct!</h4>
                    <p><strong>ANS:</strong> Heparin can be administered subcutaneously (for prophylaxis) and intravenously (IV), either as an IV bolus or in IV fluid for continuous infusion. It is NOT given orally.</p>
                </div>
            </div>

            <div class="fill-in-the-blank">
                <p>3. Why was an aPTT test ordered? How would you determine whether the patient is within the desired range? Explain your answer.</p>
                <textarea id="cs_q3_text" placeholder="Type your answer here."></textarea>
                <button class="submit-btn" id="submit_cs_q3_text">Check My Answer!</button>
                <div class="feedback" id="cs_q3_text_feedback"></div>
                <div class="rationale" id="cs_q3_text_rationale">
                    <h4>Rationale: Why this answer is correct!</h4>
                    <p><strong>ANS:</strong> An aPTT test was ordered to monitor the therapeutic effect of heparin. Heparin prolongs clotting time, and the aPTT (activated partial thromboplastin time) is the laboratory test used to monitor heparin therapy. To determine if the patient is within the desired range, the aPTT result should be compared to the control value (or the facility's therapeutic range). The desired therapeutic range for aPTT is typically 1.5 to 2.5 times the control value (e.g., if control is 30 seconds, therapeutic is 45-75 seconds), or a specific range like 30-85 seconds depending on the lab and clinical situation. This range indicates that the heparin dose is effective in preventing new clots without causing excessive bleeding.</p>
                </div>
            </div>

            <p class="case-study">After 5 days of heparin therapy, the patient was prescribed oral warfarin 5 mg daily. An INR test was ordered.</p>

            <div class="fill-in-the-blank">
                <p>4. What is the pharmacologic action of warfarin? Is the warfarin dose within the safe daily dosage range? Explain your answer.</p>
                <textarea id="cs_q4_text" placeholder="Type your answer here."></textarea>
                <button class="submit-btn" id="submit_cs_q4_text">Check My Answer!</button>
                <div class="feedback" id="cs_q4_text_feedback"></div>
                <div class="rationale" id="cs_q4_text_rationale">
                    <h4>Rationale: Why this answer is correct!</h4>
                    <p><strong>ANS:</strong> The pharmacologic action of warfarin is to inhibit the hepatic synthesis of vitamin K, which in turn affects the clotting factors II (prothrombin), VII, IX, and X. This prevents the formation of clots. The initial warfarin dose of 5 mg/day is a common starting dose for adults, making it within the safe daily dosage range. Maintenance doses typically range from 2–10 mg/day, adjusted based on INR to achieve the target therapeutic level.</p>
                </div>
            </div>

            <div class="fill-in-the-blank">
                <p>5. What are the half-life and protein binding for warfarin? If a patient takes a drug that is highly protein bound, would there be a drug interaction? Explain your answer.</p>
                <textarea id="cs_q5_text" placeholder="Type your answer here."></textarea>
                <button class="submit-btn" id="submit_cs_q5_text">Check My Answer!</button>
                <div class="feedback" id="cs_q5_text_feedback"></div>
                <div class="rationale" id="cs_q5_text_rationale">
                    <h4>Rationale: Why this answer is correct!</h4>
                    <p><strong>ANS:</strong> The half-life of warfarin is 20–60 hours. It is highly protein bound (97%). Yes, if a patient takes another drug that is also highly protein bound, there would likely be a drug interaction. This is because both drugs would compete for the same protein-binding sites. If the other drug displaces warfarin from its protein-binding sites, it would increase the amount of "free" (unbound) warfarin in the bloodstream, which is the active form of the drug. This can lead to an exaggerated anticoagulant effect and significantly increase the risk of bleeding.</p>
                </div>
            </div>

            <div class="fill-in-the-blank">
                <p>6. Why was an INR ordered for the patient? What is the desired range?</p>
                <textarea id="cs_q6_text" placeholder="Type your answer here."></textarea>
                <button class="submit-btn" id="submit_cs_q6_text">Check My Answer!</button>
                <div class="feedback" id="cs_q6_text_feedback"></div>
                <div class="rationale" id="cs_q6_text_rationale">
                    <h4>Rationale: Why this answer is correct!</h4>
                    <p><strong>ANS:</strong> An INR (International Normalized Ratio) was ordered to monitor the therapeutic effect of warfarin. The INR standardizes the PT (prothrombin time) results from different laboratories, ensuring consistent monitoring regardless of the specific reagents used. The desired therapeutic INR range for most patients on warfarin therapy, such as for thrombophlebitis, is typically 2 to 3.</p>
                </div>
            </div>

            <div class="fill-in-the-blank">
                <p>7. What serious adverse reactions could result with prolonged use or large doses of warfarin?</p>
                <textarea id="cs_q7_text" placeholder="Type your answer here."></textarea>
                <button class="submit-btn" id="submit_cs_q7_text">Check My Answer!</button>
                <div class="feedback" id="cs_q7_text_feedback"></div>
                <div class="rationale" id="cs_q7_text_rationale">
                    <h4>Rationale: Why this answer is correct!</h4>
                    <p><strong>ANS:</strong> With prolonged use or large doses of warfarin, the most serious adverse reaction is **hemorrhage (bleeding)**, which can be internal or external. This includes GI bleeding, intracranial bleeding, ocular hemorrhage, and hematuria. Other serious adverse reactions can include purple-toe syndrome, bone fracture, hypotension, and chest pain.</p>
                </div>
            </div>

            <div class="fill-in-the-blank">
                <p>8. What patient teaching interventions should the nurse include? List three interventions.</p>
                <textarea id="cs_q8_text" placeholder="Type your answer here."></textarea>
                <button class="submit-btn" id="submit_cs_q8_text">Check My Answer!</button>
                <div class="feedback" id="cs_q8_text_feedback"></div>
                <div class="rationale" id="cs_q8_text_rationale">
                    <h4>Rationale: Why this answer is correct!</h4>
                    <p><strong>ANS:</strong> The nurse should include patient teaching interventions such as (any three of the following):</p>
                    <ul>
                        <li>Advise patients to use a **soft toothbrush** to prevent gums from bleeding.</li>
                        <li>Warn patients to shave with an **electric razor**.</li>
                        <li>Advise patients to have **laboratory tests (INR) performed as ordered** and to understand that the warfarin dose is regulated by these results.</li>
                        <li>Suggest that patients **carry a medical identification card or wear a MedicAlert bracelet** stating they are on warfarin.</li>
                        <li>Encourage patients **not to smoke**, as it increases drug metabolism.</li>
                        <li>Tell patients to **check with a healthcare provider before taking any over-the-counter (OTC) drugs**, especially aspirin or NSAIDs (use acetaminophen instead).</li>
                        <li>Inform patients that many **herbal products interact with warfarin** and may increase bleeding or decrease effectiveness.</li>
                        <li>Warn patients to **report any signs of bleeding** (petechiae, ecchymosis, tarry stools, bleeding gums, epistaxis, hematuria) immediately.</li>
                        <li>Advise patients to **avoid large amounts of green, leafy vegetables and other vitamin K-rich foods** or to maintain consistent intake.</li>
                        <li>Teach patients to control external hemorrhage from injuries by applying firm, direct pressure.</li>
                    </ul>
                </div>
            </div>

            <div class="fill-in-the-blank">
                <p>9. Months later, the patient has hematemesis. What nursing action should be taken?</p>
                <textarea id="cs_q9_text" placeholder="Type your answer here."></textarea>
                <button class="submit-btn" id="submit_cs_q9_text">Check My Answer!</button>
                <div class="feedback" id="cs_q9_text_feedback"></div>
                <div class="rationale" id="cs_q9_text_rationale">
                    <h4>Rationale: Why this answer is correct!</h4>
                    <p><strong>ANS:</strong> Hematemesis (vomiting blood) is a sign of significant GI bleeding and a serious adverse reaction to warfarin, indicating a potential overdose or excessive anticoagulation. The immediate nursing actions should include:</p>
                    <ul>
                        <li>**Stop the warfarin administration immediately.**</li>
                        <li>**Notify the healthcare provider STAT.**</li>
                        <li>**Assess vital signs** frequently (e.g., every 5-15 minutes) to monitor for signs of hypovolemic shock (tachycardia, hypotension).</li>
                        <li>**Assess for other signs of bleeding** (melena/tarry stools, petechiae, ecchymosis, hematuria).</li>
                        <li>**Prepare to administer anticoagulant antagonists** (e.g., Vitamin K, fresh frozen plasma) as ordered by the provider.</li>
                        <li>**Obtain STAT lab work** including INR, CBC (hemoglobin, hematocrit, platelet count).</li>
                        <li>**Maintain NPO status** if active vomiting.</li>
                        <li>**Initiate IV access** if not already present, or ensure patency of existing IV, for fluid resuscitation or blood product administration.</li>
                        <li>**Be prepared for potential endoscopy** or other interventions to identify and control the bleeding source.</li>
                    </ul>
                </div>
            </div>
            <div class="recap">
                <h4>Recap: Case Study Takeaways</h4>
                <ul>
                    <li>Heparin administration involves IV bolus and subcutaneous dosing, monitored by aPTT.</li>
                    <li>Warfarin is an oral vitamin K antagonist, monitored by INR, with a long half-life and high protein binding.</li>
                    <li>**Key risks for both:** Bleeding (hemorrhage).</li>
                    <li>**Patient teaching is crucial** for safety (electric razor, soft toothbrush, avoiding interacting drugs/herbs/foods, recognizing bleeding signs).</li>
                    <li>**Hematemesis is an emergency; stop drug, notify provider, prepare for reversal and support.**</li>
                </ul>
            </div>
        </section>

        <section id="review-questions">
            <h2>15. Module Review Questions: Test Your Knowledge!</h2>

            <div class="question-card" id="q1_review">
                <p>1. A patient is placed on heparin, and the nurse acknowledges that heparin is effective for preventing clot formation in patients who have which disorder(s)? (Select all that apply.)</p>
                <div class="options">
                    <label><input type="checkbox" name="q1_review_option" value="a"> a. Coronary thrombosis</label>
                    <label><input type="checkbox" name="q1_review_option" value="b"> b. Acute myocardial infarction</label>
                    <label><input type="checkbox" name="q1_review_option" value="c"> c. Deep vein thrombosis</label>
                    <label><input type="checkbox" name="q1_review_option" value="d"> d. Hemorrhagic stroke</label>
                    <label><input type="checkbox" name="q1_review_option" value="e"> e. Disseminated intravascular coagulation</label>
                </div>
                <button class="submit-btn" id="submit_q1_review">Submit Answer</button>
                <div class="feedback" id="q1_review_feedback"></div>
            </div>

            <div class="question-card" id="q2_review">
                <p>2. A patient who received heparin begins to bleed. The nurse anticipates that the health care provider will order which antidote?</p>
                <div class="options">
                    <label><input type="radio" name="q2_review_option" value="a"> a. Protamine sulfate</label>
                    <label><input type="radio" name="q2_review_option" value="b"> b. Phytonadione</label>
                    <label><input type="radio" name="q2_review_option" value="c"> c. Aminocaproic acid</label>
                    <label><input type="radio" name="q2_review_option" value="d"> d. Potassium chloride</label>
                </div>
                <button class="submit-btn" id="submit_q2_review">Submit Answer</button>
                <div class="feedback" id="q2_review_feedback"></div>
            </div>

            <div class="question-card" id="q3_review">
                <p>3. A patient is prescribed enoxaparin. The nurse knows that low-molecular-weight heparin has what kind of half-life?</p>
                <div class="options">
                    <label><input type="radio" name="q3_review_option" value="a"> a. A longer half-life than heparin</label>
                    <label><input type="radio" name="q3_review_option" value="b"> b. A shorter half-life than heparin</label>
                    <label><input type="radio" name="q3_review_option" value="c"> c. The same half-life as heparin</label>
                    <label><input type="radio" name="q3_review_option" value="d"> d. A four-times shorter half-life than heparin</label>
                </div>
                <button class="submit-btn" id="submit_q3_review">Submit Answer</button>
                <div class="feedback" id="q3_review_feedback"></div>
            </div>

            <div class="question-card" id="q4_review">
                <p>4. A patient had an orthopedic surgery and is prescribed enoxaparin. What would the nurse teach the patient and/or family members about this low-molecular-weight heparin before discharge?</p>
                <div class="options">
                    <label><input type="radio" name="q4_review_option" value="a"> a. Visual demonstration of intramuscular heparin administration is recommended.</label>
                    <label><input type="radio" name="q4_review_option" value="b"> b. Prothrombin time and international normalized ratio monitoring will be done weekly.</label>
                    <label><input type="radio" name="q4_review_option" value="c"> c. Avoidance of green leafy vegetables is recommended.</label>
                    <label><input type="radio" name="q4_review_option" value="d"> d. Watch for bleeding or excessive bruising.</label>
                </div>
                <button class="submit-btn" id="submit_q4_review">Submit Answer</button>
                <div class="feedback" id="q4_review_feedback"></div>
            </div>

            <div class="question-card" id="q5_review">
                <p>5. A patient is being changed from an injectable anticoagulant to an oral anticoagulant. Which anticoagulant does the nurse realize is administered orally?</p>
                <div class="options">
                    <label><input type="radio" name="q5_review_option" value="a"> a. Enoxaparin</label>
                    <label><input type="radio" name="q5_review_option" value="b"> b. Warfarin</label>
                    <label><input type="radio" name="q5_review_option" value="c"> c. Bivalirudin</label>
                    <label><input type="radio" name="q5_review_option" value="d"> d. Dalteparin</label>
                    <label><input type="radio" name="q5_review_option" value="e"> e. Tenecteplase</label>
                    <label><input type="radio" name="q5_review_option" value="f"> f. Fondaparinux</label>
                </div>
                <button class="submit-btn" id="submit_q5_review">Submit Answer</button>
                <div class="feedback" id="q5_review_feedback"></div>
            </div>

            <div class="question-card" id="q6_review">
                <p>6. A patient is taking warfarin 5 mg/day for atrial fibrillation. The patient’s international normalized ratio is 3.8. The nurse would consider the international normalized ratio to be what?</p>
                <div class="options">
                    <label><input type="radio" name="q6_review_option" value="a"> a. Within normal range</label>
                    <label><input type="radio" name="q6_review_option" value="b"> b. Elevated range</label>
                    <label><input type="radio" name="q6_review_option" value="c"> c. Low range</label>
                    <label><input type="radio" name="q6_review_option" value="d"> d. Low-average range</label>
                </div>
                <button class="submit-btn" id="submit_q6_review">Submit Answer</button>
                <div class="feedback" id="q6_review_feedback"></div>
            </div>

            <div class="question-card" id="q7_review">
                <p>7. Cilostazol is being prescribed for a patient with coronary artery disease. The nurse understands that which of the following is the major purpose for antiplatelet drug therapy?</p>
                <div class="options">
                    <label><input type="radio" name="q7_review_option" value="a"> a. Dissolve the blood clot</label>
                    <label><input type="radio" name="q7_review_option" value="b"> b. Decrease tissue necrosis</label>
                    <label><input type="radio" name="q7_review_option" value="c"> c. Inhibit hepatic synthesis of vitamin K</label>
                    <label><input type="radio" name="q7_review_option" value="d"> d. Suppress platelet aggregation</label>
                </div>
                <button class="submit-btn" id="submit_q7_review">Submit Answer</button>
                <div class="feedback" id="q7_review_feedback"></div>
            </div>

        </section>
        <section id="drug-mastery-quiz">
            <h2>16. Drug Mastery Challenge: Let's Master These Clotting Meds!</h2>
            <p>Ready to test your knowledge on the drugs for anticoagulation, antiplatelet therapy, and thrombolysis? Go through each card and see if you can recall the key information!</p>
            <button id="startQuizBtn">Start Drug Mastery Challenge!</button>

            <div class="quiz-card" id="drugQuizCard">
                <div class="progress-tracker">Card <span id="currentCardNum">1</span> of <span id="totalCardsNum">0</span></div>
                <h4 id="drugName">Drug Name Goes Here</h4>
                <p id="drugQuestion">Question about the drug will appear here.</p>

                <div class="quiz-controls">
                    <button id="showAnswerBtn">Show Answer</button>
                </div>

                <div id="answerFeedback">
                    <h5>Answer: <span id="answerType"></span></h5>
                    <p id="answerContent"></p>
                </div>

                <div id="masteryButtons" style="display: none;">
                    <p>Did you get it right?</p>
                    <button id="correctBtn">Yes, I knew it!</button>
                    <button id="incorrectBtn">No, I need to review.</button>
                </div>
            </div>

            <div id="quizSummary">
                <h4>Challenge Complete!</h4>
                <p>You've gone through all the drugs!</p>
                <p>Mastered on first try: <span id="masteredCount">0</span></p>
                <p>Needed review: <span id="missedCount">0</span></p>
                <button id="restartQuizBtn">Restart Full Quiz</button>
                <button id="reviewMissedBtn">Review Missed Drugs</button>
            </div>
        </section>

        <footer>
            <p>&copy; 2025 Chapter 43: Anticoagulants, Antiplatelets, and Thrombolytics Learning Module. Designed for focused learning.</p>
        </footer>
    </div>

    <div id="clockOutOverlay">
        <div id="clockOutContent">
            <h2>Clock Out!</h2>
            <p>Take a moment to reset your focus. Your module will resume in:</p>
            <div id="brainEmoji">🧠</div> <div id="countdownTimer">00:30</div>
        </div>
    </div>
    <script>
        // ==========================================
        // Drug Data (This is the only part that can safely sit outside DOMContentLoaded)
        // ==========================================
        const drugs = [
            {
                name: "Heparin",
                class: "Anticoagulant (Indirect Thrombin Inhibitor)",
                keyActions: "Enhances antithrombin III, which inactivates thrombin and other clotting factors, preventing fibrin formation. Used for rapid anticoagulation in DVT, PE, evolving stroke, open-heart surgery, DIC.",
                sideEffects: "Bleeding, hemorrhage, hematoma, thrombocytopenia (HIT), epistaxis, hematuria, alopecia, elevated hepatic enzymes, nausea, vomiting, injection-site reaction.",
                nursingConsiderations: "Administered subcut or IV (bolus/continuous). Monitor aPTT (1.5-2.5x control). Monitor platelet count for HIT. Antidote: Protamine Sulfate. Do NOT give orally. Does not cross placenta. Avoid NSAIDs/aspirin. Observe for signs of bleeding."
            },
            {
                name: "Warfarin (Coumadin)",
                class: "Anticoagulant (Vitamin K Antagonist)",
                keyActions: "Inhibits hepatic synthesis of vitamin K-dependent clotting factors (II, VII, IX, X), preventing clot formation. Used for long-term prevention of DVT, PE, stroke in AFib, and with prosthetic heart valves.",
                sideEffects: "Bleeding, hemorrhage (major adverse effect), GI bleeding, ecchymoses, hematuria, petechiae, alopecia, purple-toe syndrome.",
                nursingConsiderations: "Administered orally. Monitor PT/INR (therapeutic INR 2-3, 2.5-3.5 for mechanical valves). Antidote: Phytonadione (Vitamin K) for overdose; Fresh Frozen Plasma (FFP) for acute bleeding. Many drug/food/herb interactions (highly protein-bound). Avoid aspirin/NSAIDs (use acetaminophen). Does cross placenta; contraindicated in pregnancy."
            },
            {
                name: "Enoxaparin (Lovenox)",
                class: "Low-Molecular-Weight Heparin (LMWH)",
                keyActions: "Inactivates Factor Xa (primarily), less able to inactivate thrombin directly. Prevents DVT and PE, especially post-orthopedic/abdominal surgery.",
                sideEffects: "Bleeding, hematoma, fever, anemia, peripheral edema, elevated liver enzymes.",
                nursingConsiderations: "Administered subcutaneously once or twice daily. No routine aPTT monitoring required. Lower bleeding risk than unfractionated heparin. Antidote: Protamine Sulfate. Contraindicated in stroke, peptic ulcers, blood anomalies, eye/brain/spinal surgery. Can be administered at home. Do not confuse with enoxacin or Lotronex."
            },
            {
                name: "Rivaroxaban (Xarelto)",
                class: "Selective Factor Xa Inhibitor (Oral Anticoagulant)",
                keyActions: "Selectively blocks activity of clotting factor Xa to prevent clot formation. Used for prevention/treatment of DVT/PE, and stroke/systemic embolism in nonvalvular atrial fibrillation.",
                sideEffects: "Bleeding (GI, ocular, intracranial), abdominal/back pain, pruritus, dyspepsia.",
                nursingConsiderations: "Administered orally once or twice daily. Does not require routine coagulation monitoring. Major adverse effect is bleeding. Not recommended for patients weighing less than 50 kg due to increased bleeding risk. No specific antidote listed in provided text (though reversal agents like Andexxa exist clinically)."
            },
            {
                name: "Apixaban (Eliquis)",
                class: "Selective Factor Xa Inhibitor (Oral Anticoagulant)",
                keyActions: "Selectively blocks activity of clotting factor Xa to prevent clot formation. Used to prevent/treat DVT/PE and for prevention of stroke/systemic embolism in nonvalvular atrial fibrillation.",
                sideEffects: "Hematoma, anemia, bleeding (epistaxis, hematuria, menorrhagia, hemoptysis, hematemesis, ocular, vaginal, GI, intracranial), hypotension.",
                nursingConsiderations: "Administered orally twice daily. Does not require routine coagulation monitoring. Major adverse effect is bleeding. No specific antidote listed in provided text (though reversal agents like Andexxa exist clinically). Not recommended for patients weighing less than 50 kg."
            },
            {
                name: "Dabigatran (Pradaxa)",
                class: "Direct Thrombin Inhibitor (Oral Anticoagulant)",
                keyActions: "Directly inhibits thrombin from converting fibrinogen to fibrin, preventing clot formation. Used for prevention of stroke/systemic embolism in nonvalvular atrial fibrillation and for prophylaxis/treatment of DVT/PE.",
                sideEffects: "Bleeding (GI), headache, pharyngitis, epistaxis, nausea, vomiting, menorrhagia, pruritus, edema.",
                nursingConsiderations: "Administered orally twice daily. Does not require routine coagulation monitoring. More expensive than older anticoagulants. No specific antidote listed in provided text (though Idarucizumab (Praxbind) exists clinically)."
            },
            {
                name: "Aspirin (ASA)",
                class: "Antiplatelet (COX Inhibitor)",
                keyActions: "Inhibits cyclooxygenase (COX), preventing platelets from synthesizing thromboxane A2 (TxA2) needed for aggregation. Used for MI/stroke prevention (primary & secondary) and TIA prophylaxis.",
                sideEffects: "Abdominal pain, nausea, dyspepsia, gastritis, GI bleeding, intracranial bleeding, epistaxis.",
                nursingConsiderations: "Low-dose therapy (75-325 mg/day). Discontinue at least 7 days before surgery. Avoid with warfarin (increases bleeding risk). Many herbal interactions can increase bleeding. Use acetaminophen for pain."
            },
            {
                name: "Clopidogrel (Plavix)",
                class: "Antiplatelet (ADP Antagonist)",
                keyActions: "Inhibits platelet aggregation by blocking ADP from binding to the platelet ADP receptor. Used after MI/stroke to prevent a second event, also for unstable angina and TIA.",
                sideEffects: "Abdominal pain, dizziness, headaches, hematoma, dyspepsia, diarrhea, constipation, purpura, peripheral edema, rash, pruritus, epistaxis.",
                nursingConsiderations: "Often used with aspirin. Discontinue 7 days preceding surgery. Contraindicated in active bleeding (intracranial hemorrhage, GI bleeding). Many drug/herb interactions increasing bleeding risk. Life-threatening: Agranulocytosis, aplastic anemia, thrombocytopenia, Stevens-Johnson syndrome."
            },
            {
                name: "Alteplase (tPA, Activase)",
                class: "Thrombolytic Agent (Tissue Plasminogen Activator)",
                keyActions: "Promotes conversion of plasminogen to plasmin, an enzyme that digests the fibrin matrix of clots (fibrinolysis). Used to dissolve existing clots in AMI, ischemic stroke, PE, occluded IV catheters.",
                sideEffects: "Epistaxis, infection, ecchymosis, nausea, vomiting, rash.",
                nursingConsiderations: "Administered IV. **Crucial timing:** AMI (within 3-4h), ischemic stroke (within 3h). Major adverse effect is **hemorrhage**. Monitor frequently for bleeding (every 15min initially). Monitor ECG for reperfusion dysrhythmias. Avoid aspirin/NSAIDs. Antidote: Aminocaproic acid."
            },
            {
                name: "Protamine Sulfate",
                class: "Anticoagulant Antagonist",
                keyActions: "Reverses the anticoagulant action of Heparin and LMWHs by binding to them and forming a stable complex. Used for heparin overdose or excessive bleeding.",
                sideEffects: "Hypotension, flushing, bradycardia, fatigue, bleeding, pulmonary edema, dyspnea.",
                nursingConsiderations: "Administered IV. Dosage dependent on amount of heparin to be neutralized. Monitor vital signs closely during administration."
            },
            {
                name: "Phytonadione (Vitamin K1)",
                class: "Anticoagulant Antagonist / Vitamin",
                keyActions: "Reverses the anticoagulant action of Warfarin by promoting hepatic synthesis of vitamin K-dependent clotting factors. Used for warfarin overdose or uncontrollable bleeding.",
                sideEffects: "Anaphylaxis (with IV), dizziness, flushing, dysgeusia, dyspnea, hyperhidrosis, tachycardia, hypotension.",
                nursingConsiderations: "Administered orally or IV (slow infusion). Takes 24-48 hours to be effective. Excessive doses can make warfarin ineffective for 1-2 weeks. For acute severe bleeding, Fresh Frozen Plasma (FFP) is used for immediate effect."
            },
            {
                name: "Aminocaproic Acid (Amicar)",
                class: "Hemostatic / Antithrombotic Antagonist",
                keyActions: "Inhibits plasminogen activation, thereby preventing plasmin formation and inhibiting fibrinolysis (clot breakdown). Used to stop bleeding caused by thrombolytic therapy or hyperfibrinolysis.",
                sideEffects: "Hypotension, headache, dyspnea, edema, dizziness, bradycardia, vision impairment, nausea, diarrhea.",
                nursingConsiderations: "Administered orally or IV. Monitor for effectiveness in stopping bleeding and for adverse effects."
            }
        ];

        // ==========================================
        // ALL other JavaScript code and functions MUST be inside this single DOMContentLoaded listener.
        // This ensures all HTML elements are available when the script tries to access them.
        // ==========================================
        document.addEventListener('DOMContentLoaded', () => {

            // --- QUIZ VARIABLES AND ELEMENT SELECTIONS ---
            let currentQuizDrugsCopy = [];
            let currentDrugIndex = 0;
            let masteredDrugs = [];
            let missedDrugs = [];
            const questionTypes = ['class', 'keyActions', 'sideEffects', 'nursingConsiderations'];

            const startQuizBtn = document.getElementById('startQuizBtn');
            const drugQuizCard = document.getElementById('drugQuizCard');
            const drugNameEl = document.getElementById('drugName');
            const drugQuestionEl = document.getElementById('drugQuestion');
            const showAnswerBtn = document.getElementById('showAnswerBtn');
            const answerFeedbackEl = document.getElementById('answerFeedback');
            const answerTypeEl = document.getElementById('answerType');
            const answerContentEl = document.getElementById('answerContent');
            const masteryButtons = document.getElementById('masteryButtons');
            const correctBtn = document.getElementById('correctBtn');
            const incorrectBtn = document.getElementById('incorrectBtn');
            const quizSummary = document.getElementById('quizSummary');
            const masteredCountEl = document.getElementById('masteredCount');
            const missedCountEl = document.getElementById('missedCount');
            const restartQuizBtn = document.getElementById('restartQuizBtn');
            const reviewMissedBtn = document.getElementById('reviewMissedBtn');
            const currentCardNumEl = document.getElementById('currentCardNum');
            const totalCardsNumEl = document.getElementById('totalCardsNum');

            // --- MODULE PROGRESS BAR VARIABLES ---
            const moduleProgressBar = document.getElementById('moduleProgressBar');
            let completedSectionsCount = 0; // Tracks number of completed logical sections

            // Define all section IDs that should count towards progress
            const completableSectionIds = new Set([
                'objectives', 'introduction', 'thrombus-formation', 'anticoagulants', 'heparin', 'lmwh',
                'dtis', 'oral-anticoagulants', 'factor-xa-inhibitors', 'nursing-process-anticoag',
                'anticoagulant-antagonists', 'antiplatelet-drugs', 'thrombolytics',
                'nursing-process-thrombolytics', 'case-study', 'review-questions', 'drug-mastery-quiz',
                'quick-note-area' // Ensure quick notes count as completable
            ]);

            const totalSections = completableSectionIds.size;

            // --- HELPER FUNCTIONS ---

            function updateProgressBar() {
                const progress = (completedSectionsCount / totalSections) * 100;
                moduleProgressBar.style.width = `${progress}%`;
            }

            function markSectionCompleted(sectionId) {
                const navLink = document.getElementById('nav-' + sectionId);
                if (navLink && !navLink.classList.contains('completed')) {
                    navLink.classList.add('completed');
                    if (completableSectionIds.has(sectionId)) {
                        completedSectionsCount++;
                        updateProgressBar();
                        if (completedSectionsCount > 0 && completedSectionsCount % 3 === 0 && completedSectionsCount !== totalSections) {
                            showMicroBreakPrompt();
                        }
                    }
                }
            }

            // Mark initial sections as completed on load
            markSectionCompleted('objectives');
            markSectionCompleted('quick-note-area');

            // --- Manual scrolling for navigation links ---
            document.querySelectorAll('nav ul li a').forEach(link => {
                link.addEventListener('click', function(event) {
                    event.preventDefault();
                    const targetId = this.id.replace('nav-', '');
                    const targetSection = document.getElementById(targetId);
                    if (targetSection) {
                        targetSection.scrollIntoView({ behavior: 'smooth', block: 'start' });
                    }
                });
            });


            // toggleReveal function
            function toggleReveal(button) {
                const content = button.nextElementSibling;
                if (content.style.display === "block") {
                    content.style.display = "none";
                    button.textContent = button.dataset.originalText;
                } else {
                    content.style.display = "block";
                    button.dataset.originalText = button.textContent;
                    button.textContent = "Click to Hide Details";
                    const parentSection = button.closest('section');
                    if (parentSection && parentSection.id) {
                        markSectionCompleted(parentSection.id);
                    }
                }
            }

            // --- Question Checking Functions ---
            function checkAnswer(questionId, correctAnswer) {
                const questionCard = document.getElementById(questionId);
                const selectedOption = questionCard.querySelector('input[name="' + questionId + '_option"]:checked');
                const feedbackDiv = questionCard.querySelector('.feedback');

                questionCard.querySelectorAll('input[type="radio"]').forEach(input => input.disabled = true);
                const submitBtn = questionCard.querySelector('.submit-btn');
                if (submitBtn) {
                    submitBtn.disabled = true;
                }

                if (!selectedOption) {
                    feedbackDiv.textContent = "Oops! Please pick an answer before checking.";
                    feedbackDiv.className = 'feedback incorrect';
                    feedbackDiv.style.display = 'block';
                    return;
                }

                if (selectedOption.value === correctAnswer) {
                    feedbackDiv.textContent = "Awesome! That's correct. Keep up the great work!";
                    feedbackDiv.className = 'feedback correct';
                } else {
                    feedbackDiv.textContent = `Not quite! The correct answer was: ${correctAnswer.toUpperCase()}. Review the material and try to understand why.`;
                    feedbackDiv.className = 'feedback incorrect';
                }
                feedbackDiv.style.display = 'block';
                markSectionCompleted(questionCard.closest('section').id);
            }

            function checkMultipleAnswers(questionId, correctAnswers) {
                const questionCard = document.getElementById(questionId);
                const selectedOptions = Array.from(questionCard.querySelectorAll('input[name="' + questionId + '_option"]:checked')).map(input => input.value);
                const feedbackDiv = questionCard.querySelector('.feedback');

                questionCard.querySelectorAll('input[type="checkbox"]').forEach(input => input.disabled = true);
                const submitBtn = questionCard.querySelector('.submit-btn');
                if (submitBtn) {
                    submitBtn.disabled = true;
                }

                if (selectedOptions.length === 0) {
                    feedbackDiv.textContent = "Don't forget to select your answers!";
                    feedbackDiv.className = 'feedback incorrect';
                    feedbackDiv.style.display = 'block';
                    return;
                }

                const isCorrect = correctAnswers.every(answer => selectedOptions.includes(answer)) &&
                                       selectedOptions.every(answer => correctAnswers.includes(answer));

                if (isCorrect) {
                    feedbackDiv.textContent = "Fantastic! You got all the correct points!";
                    feedbackDiv.className = 'feedback correct';
                } else {
                    feedbackDiv.textContent = `Hold on! Double-check the options and review the related content. You might have missed something or picked too many/too few. Correct answers were: ${correctAnswers.join(', ').toUpperCase()}.`;
                    feedbackDiv.className = 'feedback incorrect';
                }
                feedbackDiv.style.display = 'block';
                markSectionCompleted(questionCard.closest('section').id);
            }

            function checkCaseStudyFreeText(questionId, rationaleId) {
                const textarea = document.getElementById(questionId + '_text');
                const feedbackDiv = document.getElementById(questionId + '_text_feedback');
                const rationaleDiv = document.getElementById(rationaleId);
                const submitBtn = document.getElementById('submit_' + questionId + '_text');

                textarea.disabled = true;
                submitBtn.disabled = true;

                feedbackDiv.textContent = "Good attempt! Compare your answer with the detailed rationale below to refine your understanding. Keep up the great work!";
                feedbackDiv.className = 'feedback correct';
                feedbackDiv.style.display = 'block';
                rationaleDiv.style.display = 'block';
                markSectionCompleted(rationaleDiv.closest('section').id);
            }


            // --- DRUG MASTERY QUIZ FUNCTIONS ---
            function shuffleArray(array) {
                for (let i = array.length - 1; i > 0; i--) {
                    const j = Math.floor(Math.random() * (i + 1));
                    [array[i], array[j]] = [array[j], array[i]];
                }
                return array;
            }

            function startQuiz(reviewMode = false) {
                if (!reviewMode) {
                    currentQuizDrugsCopy = shuffleArray([...drugs]);
                    masteredDrugs = [];
                    missedDrugs = [];
                } else {
                    if (missedDrugs.length === 0) {
                        alert("Fantastic! You've mastered all the drugs in the review pile. Starting a new full quiz!");
                        currentQuizDrugsCopy = shuffleArray([...drugs]);
                        masteredDrugs = [];
                        missedDrugs = [];
                    } else {
                        currentQuizDrugsCopy = shuffleArray([...missedDrugs]);
                        missedDrugs = [];
                    }
                }

                currentDrugIndex = 0;
                startQuizBtn.style.display = 'none';
                drugQuizCard.style.display = 'block';
                quizSummary.style.display = 'none';
                displayCurrentCard();
                markSectionCompleted('drug-mastery-quiz');
            }

            function displayCurrentCard() {
                if (currentDrugIndex >= currentQuizDrugsCopy.length) {
                    showQuizSummary();
                    return;
                }

                const currentDrug = currentQuizDrugsCopy[currentDrugIndex];
                const randomQuestionType = questionTypes[Math.floor(Math.random() * questionTypes.length)];

                drugNameEl.textContent = currentDrug.name;
                currentCardNumEl.textContent = currentDrugIndex + 1;
                totalCardsNumEl.textContent = currentQuizDrugsCopy.length;

                let questionText = '';
                switch (randomQuestionType) {
                    case 'class':
                        questionText = `What is the **drug class** for ${currentDrug.name}?`;
                        break;
                    case 'keyActions':
                        questionText = `What is a **key action or use** of ${currentDrug.name}?`;
                        break;
                    case 'sideEffects':
                        questionText = `Name one or two **common side effects** of ${currentDrug.name}.`;
                        break;
                    case 'nursingConsiderations':
                        questionText = `What is an **important nursing consideration** when administering ${currentDrug.name}?`;
                        break;
                }
                drugQuestionEl.innerHTML = questionText;

                answerFeedbackEl.style.display = 'none';
                masteryButtons.style.display = 'none';
                showAnswerBtn.style.display = 'block';

                drugQuizCard.dataset.currentQuestionType = randomQuestionType;
            }

            function showAnswer() {
                const currentDrug = currentQuizDrugsCopy[currentDrugIndex];
                const questionType = drugQuizCard.dataset.currentQuestionType;

                answerTypeEl.textContent = questionType.replace(/([A-Z])/g, ' $1').toLowerCase().replace(/^./, str => str.toUpperCase());

                let content = '';
                switch (questionType) {
                    case 'class':
                        content = currentDrug.class;
                        break;
                    case 'keyActions':
                        content = currentDrug.keyActions;
                        break;
                    case 'sideEffects':
                        content = currentDrug.sideEffects;
                        break;
                    case 'nursingConsiderations':
                        content = currentDrug.nursingConsiderations;
                        break;
                }
                answerContentEl.textContent = content;

                answerFeedbackEl.style.display = 'block';
                showAnswerBtn.style.display = 'none';
                masteryButtons.style.display = 'flex';
            }

            function handleMastery(isCorrect) {
                const currentDrug = currentQuizDrugsCopy[currentDrugIndex];
                if (isCorrect) {
                    if (!missedDrugs.includes(currentDrug)) {
                        masteredDrugs.push(currentDrug);
                    }
                    const missedIndex = missedDrugs.indexOf(currentDrug);
                    if (missedIndex > -1) {
                        missedDrugs.splice(missedIndex, 1);
                    }

                } else {
                    if (!missedDrugs.includes(currentDrug)) {
                        missedDrugs.push(currentDrug);
                    }
                    const masteredIndex = masteredDrugs.indexOf(currentDrug);
                    if (masteredIndex > -1) {
                        masteredDrugs.splice(masteredIndex, 1);
                    }
                }
                masteryButtons.style.display = 'none';

                setTimeout(() => {
                    currentDrugIndex++;
                    displayCurrentCard();
                }, 1500);
            }

            function showQuizSummary() {
                drugQuizCard.style.display = 'none';
                quizSummary.style.display = 'block';

                const uniqueMastered = [...new Set(masteredDrugs)];
                const uniqueMissed = [...new Set(missedDrugs)];

                masteredCountEl.textContent = uniqueMastered.length;
                missedCountEl.textContent = uniqueMissed.length;
            }

            // --- EVENT LISTENERS ---

            // Attach event listeners for all reveal buttons
            document.querySelectorAll('.reveal-button').forEach(button => {
                button.addEventListener('click', function() {
                    toggleReveal(this);
                });
            });

            // Case Study Questions
            document.getElementById('submit_cs_q1_text').addEventListener('click', () => checkCaseStudyFreeText('cs_q1', 'cs_q1_text_rationale'));
            document.getElementById('submit_cs_q2_text').addEventListener('click', () => checkCaseStudyFreeText('cs_q2', 'cs_q2_text_rationale'));
            document.getElementById('submit_cs_q3_text').addEventListener('click', () => checkCaseStudyFreeText('cs_q3', 'cs_q3_text_rationale'));
            document.getElementById('submit_cs_q4_text').addEventListener('click', () => checkCaseStudyFreeText('cs_q4', 'cs_q4_text_rationale'));
            document.getElementById('submit_cs_q5_text').addEventListener('click', () => checkCaseStudyFreeText('cs_q5', 'cs_q5_text_rationale'));
            document.getElementById('submit_cs_q6_text').addEventListener('click', () => checkCaseStudyFreeText('cs_q6', 'cs_q6_text_rationale'));
            document.getElementById('submit_cs_q7_text').addEventListener('click', () => checkCaseStudyFreeText('cs_q7', 'cs_q7_text_rationale'));
            document.getElementById('submit_cs_q8_text').addEventListener('click', () => checkCaseStudyFreeText('cs_q8', 'cs_q8_text_rationale'));
            document.getElementById('submit_cs_q9_text').addEventListener('click', () => checkCaseStudyFreeText('cs_q9', 'cs_q9_text_rationale'));

            // Review Questions
            document.getElementById('submit_q1_review').addEventListener('click', () => checkMultipleAnswers('q1_review', ['a', 'b', 'c', 'e'])); // d is hemorrhagic stroke (contraindication)
            document.getElementById('submit_q2_review').addEventListener('click', () => checkAnswer('q2_review', 'a'));
            document.getElementById('submit_q3_review').addEventListener('click', () => checkAnswer('q3_review', 'a'));
            document.getElementById('submit_q4_review').addEventListener('click', () => checkAnswer('q4_review', 'd'));
            document.getElementById('submit_q5_review').addEventListener('click', () => checkAnswer('q5_review', 'b'));
            document.getElementById('submit_q6_review').addEventListener('click', () => checkAnswer('q6_review', 'b'));
            document.getElementById('submit_q7_review').addEventListener('click', () => checkAnswer('q7_review', 'd'));


            // Quiz Mastery Challenge Event Listeners
            startQuizBtn.addEventListener('click', () => startQuiz(false));
            showAnswerBtn.addEventListener('click', showAnswer);
            correctBtn.addEventListener('click', () => handleMastery(true));
            incorrectBtn.addEventListener('click', () => handleMastery(false));
            restartQuizBtn.addEventListener('click', () => startQuiz(false));
            reviewMissedBtn.addEventListener('click', () => startQuiz(true));

            // Text Size Controls
            const body = document.body;
            const increaseTextBtn = document.getElementById('increaseText');
            const decreaseTextBtn = document.getElementById('decreaseText');
            let currentFontSize = 16; // Base font size in px (matches default Open Sans)

            increaseTextBtn.addEventListener('click', () => {
                currentFontSize += 2;
                body.style.fontSize = `${currentFontSize}px`;
            });

            decreaseTextBtn.addEventListener('click', () => {
                currentFontSize -= 2;
                if (currentFontSize < 12) currentFontSize = 12; // Minimum size
                body.style.fontSize = `${currentFontSize}px`;
            });

            // Quick Notes persistence (uses localStorage)
            const quickNotesTextarea = document.getElementById('quickNotesTextarea');
            if (localStorage.getItem('anticoagModuleNotes')) { // Unique key for this module
                quickNotesTextarea.value = localStorage.getItem('anticoagModuleNotes');
            }
            quickNotesTextarea.addEventListener('input', () => {
                localStorage.setItem('anticoagModuleNotes', quickNotesTextarea.value);
            });

            // Micro-Break Prompts & Clock Out Logic
            const microBreakPromptEl = document.getElementById('microBreakPrompt');
            const breakPrompts = [
                "Quick Break! Stand up and stretch, or take a few deep breaths!",
                "Time for a 30-second mental reset. Look away from the screen for a moment!",
                "Mini-Break! Wiggle your toes or do a quick shoulder roll.",
                "Focus check! Take a sip of water and recenter. You're doing great!",
                "Short pause! How about a quick doodle or scribble for 15 seconds?"
            ];
            let breakPromptTimeout;

            const clockOutOverlay = document.getElementById('clockOutOverlay');
            const countdownTimerEl = document.getElementById('countdownTimer');
            let countdownInterval;

            function showMicroBreakPrompt() {
                if (breakPromptTimeout) {
                    clearTimeout(breakPromptTimeout);
                }
                if (countdownInterval) {
                    clearInterval(countdownInterval);
                }

                const randomChanceForClockOut = Math.random();
                const shouldTriggerClockOut = (completedSectionsCount > 0 && completedSectionsCount % 3 === 0 && randomChanceForClockOut < 0.7);

                if (shouldTriggerClockOut) {
                    startClockOut();
                } else {
                    const randomPrompt = breakPrompts[Math.floor(Math.random() * breakPrompts.length)];
                    microBreakPromptEl.textContent = randomPrompt;
                    microBreakPromptEl.style.display = 'block';
                    breakPromptTimeout = setTimeout(() => {
                        microBreakPromptEl.style.display = 'none';
                    }, 8000);
                }
            }

            function startClockOut() {
                microBreakPromptEl.style.display = 'none';

                clockOutOverlay.classList.add('active');
                document.body.classList.add('blurred');

                let timeLeft = 30;
                countdownTimerEl.textContent = '00:30';

                countdownInterval = setInterval(() => {
                    timeLeft--;

                    const minutes = Math.floor(timeLeft / 60);
                    const seconds = timeLeft % 60;

                    const formattedTime = `${String(minutes).padStart(2, '0')}:${String(seconds).padStart(2, '0')}`;
                    countdownTimerEl.textContent = formattedTime;

                    if (timeLeft <= 0) {
                        clearInterval(countdownInterval);
                        endClockOut();
                    }
                }, 1000);
            }

            function endClockOut() {
                clockOutOverlay.classList.remove('active');
                document.body.classList.remove('blurred');
                microBreakPromptEl.textContent = "Welcome back! Let's get back to it!";
                microBreakPromptEl.style.display = 'block';
                setTimeout(() => {
                    microBreakPromptEl.style.display = 'none';
                }, 5000);
            }

            // --- Initial setup calls that run once DOM is fully loaded ---
            document.querySelectorAll('.reveal-button').forEach(button => {
                button.dataset.originalText = button.textContent;
            });
            updateProgressBar();
        });
    </script>
</body>
</html>
